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!Zusammenfassung 
 Die autosomal dominante polyzystische Nierenerkrankung (ADPKD) ist eine der 
häufigsten monogen vererbten Erkrankungen, von der ∼1 von 1000 Geburten betroffen sind, und 
somit ∼750 000 Menschen in Europa. Das herausstechende Merkmal ist die Entwicklung und das 
kontinuierliche Wachstum von Zysten in beiden Nieren. Im Laufe des Lebens ersetzen die Zysten 
zunehmend das funktionelle Nierenparenchym und führen in 50% aller Fälle zwischen dem 50. 
und 60. Lebensjahr zum Erreichen eines terminalen Nierenversagens mit der Notwendigkeit die 
Nierenfunktion zu ersetzen. Die Forschung in der letzten Dekade erzielte neue Erkenntnisse zur 
ADPKD Pathogenese und verschiedene Medikamente wurden in präklinischen und klinischen 
Studien getestet. Trotz dieser Fortschritte, ist bis heute noch keine Therapie für ADPKD 
verfügbar. 
 ADPKD zeichnet sich durch eine grosse Heterogenität des Krankheitsverlaufes innerhalb 
und zwischen Familien aus. Die Gründe dafür sind bisher unbekannt. Traditionelle Parameter zur 
Evaluation des Krankheitsstadiums, wie die geschätzte glomerulare Filtrationsrate (eGFR), sind 
nicht geeignet um das Stadium der Erkrankung, vor allem zu einem frühen Zeitpunkt, exakt zu 
bestimmen. Ausreichend statistisch gepowerte Studien sind notwendig um neue Erkenntnisse 
über den Verlauf der Krankheit zu erhalten und um die Patienten zu diagnostizieren, die von 
neuen oder spezifischen Therapiemöglichkeiten am stärksten profitieren werden.  
 Im ersten Teil dieser Arbeit wird die Umsetzung einer internationalen Beobachtungsstudie 
von ADPKD Patienten in Europa beschrieben. Die EuroCYST Initiative dient als Plattform um 
die Pathogenese, Progressionsfaktoren, Mortalität, Komorbidität als auch 
gesundheitsökonomische Faktoren der ADPKD zu erforschen. Die Etablierung dieser Kohorte 
wird einen wesentlichen Beitrag zur Harmonisierung und Standardisierung des 
!Forschungsaufwandes in Europa beitragen und die Anwendung von neuen Technologien in der 
Behandlung von ADPKD sicherstellen.  
 Im zweiten und dritten Teil untersuchen wir potentielle Biomarker im Urin von ADPKD 
Patienten und testen diese auf ihre Eigenschaften das Krankheitsstadium und die 
Verlaufsprognose zu bestimmen. Unsere Ergebnisse weisen darauf hin, dass die Osmolalität, 
UACR und KIM-1 die Eigenschaft besitzen das Stadium der Erkrankung zu bestimmen. 
Hingegen NGAL, UMOD und CC16 qualifizieren sich nicht als Biomarker. Entsprechend 
unseres Wissenstandes, haben wir zum ersten Mal UMOD und CC16 in Urin von ADPKD 
berichtet. Makrohämaturie ist ein häufig berichtetes Symptom während des Verlaufs von 
ADPKD. Im Gegensatz dazu wurde mikroskopische Hämaturie nur selten untersucht. 
Mikroämaturie ist assoziiert mit verschiedenen Krankheitsindizes und könnte das Potential als 
weiterer Marker für das Erkrankungsstadium besitzen.  
 Zusammenfassend können wir mit unseren Studien neue Faktoren aufzeigen, die das 
Stadium der Erkrankung in der klinischen Praxis, möglicherweise genauer bestimmen als 
traditionell angewandte Parameter mit besonderem Fokus auf ein frühes Krankheitsstadium, in 
dem die Nierenfunktion noch nicht eingeschränkt ist und neue Therapieansätze mehr Nutzen für 
den Patienten haben werden. 
  
!Summary 
 Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common 
monogenic genetic diseases, affecting ∼1 in 1,000 live births, around ∼750,000 individuals in 
Europe. The most prominent feature is the development and continuous growth of bilateral renal 
cysts. During patients lifespan, cysts replace more and more functional renal parenchyma, 
ultimately leading to end-stage renal disease (ESRD) in 50% of the patients between their 50s 
and 60s. Research over the last decade brought new insights into the pathogenesis of ADPKD 
and various medical treatments were investigated in preclinical and clinical studies. Despite these 
advances, no disease modifying treatment for ADPKD is so far available.  
 ADPKD is characterized by a strong intra- and interfamilial variability in disease course, 
by yet unknown causes. Furthermore, traditional markers to assess disease state, like estimated 
glomerular filtration rate, are not appropriate to determine patients’ disease state, especially in the 
early course of ADPKD. Adequately powered studies are needed to gain new insights in the 
disease course and to identify those patients that would benefit most from new or specific 
medical treatments.  
 In the first part of this thesis, we describe the implementation of a large international 
observational cohort of ADPKD patients in Europe. The EuroCYST Initiative will serve as a 
scaffold and platform enabling researchers to study the pathogenesis, progression factors, 
mortality, co-morbidity as well as health economic issues relevant to ADPKD as a major cause of 
kidney disease. The establishment of this cohort will help to harmonize and standardize research 
efforts in Europe and will guarantee that new technologies can be applied to ADPKD patients. 
 In the second and third part, we investigated potential new urinary biomarkers in ADPKD 
and tested their properties for the disease state assessment and prediction. Our results indicate 
that osmolality, UACR and KIM-1 may have the property to assess disease state during early 
!ADPKD disease course, whereas NGAL, UMOD and CC16 seem not to qualify as biomarkers. 
To our knowledge, urinary UMOD and CC16 levels in ADPKD have been reported by us for the 
first time. Macrohematuria is a commonly reported symptom during the course of ADPKD. In 
contrast, microscopic hematuria has been rarely investigated. Microhematuria is associated with 
various disease indices and may serve as potential marker for disease state.  
 In summary, these studies introduce and will promote possible new determinants to more 
accurately assess disease state compared with traditional markers in clinical routine, with focus 
on early disease, when kidney function is still within normal range and when potential new 
therapies would offer most benefit to patients.  
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!Abbreviations 
ADPKD autosomal dominant polycystic kidney disease 
AKI  acute kidney injury 
AVP  arginine vasopressin 
cAMP  cyclic adenosine monophosphate 
CC16  clara cell protein 16 
CFTR  cystic fibrosis transmembrane conductance regulator 
CKD  chronic kidney disease 
eGFR  estimated glomerular filtration rate 
ESRD  end stage renal disease 
FJHN  familial juvenile hyperucemic nephropathy 
GCP  good clinical practice 
GFR  glomerular filtration rate 
GPI  glycosylphosphatidylinositol  
hrQoL  health related quality of life 
htTKV  height adjusted total kidney volume  
KIM-1  kidney injury molecule 1 
LMWP low molecular weight protein 
LVH  left ventricular hypertrophy 
MRI  magnetic resonance imaging 
mTOR  mammalian target of rapamycin 
NGAL  neutrophil gelatinase associated lipocalin  
NKCC2 sodium-potassium-cloride transporter 
PC1  polycystin 1 
!PC2  polycystin 2 
PKD  polycystic kidney disease 
PKD1  polycystic kidney disease 1 
PKD2  polycystic kidney disease 2 
PLD  polycystic liver disease 
QoL  quality of life 
RAAS  renin-angiotensin-aldosteron-system 
ROMK renal outer medullary potassium channel 
RRT  renal replacement therapy 
SOP  standard operating procedure 
SST2  somatostatin receptor 2 
TAL  thick ascending limb 
TIM-1  immunoglobulin and mucin-containing molecule 1 family 
TKV  total kidney volume  
TRPP2 transient receptor potential channel 2 
UTI  urinary tract infection 
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Autosomal Dominant Polycystic Kidney Disease !
Clinical Description 
 Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited 
kidney disease, affecting approximately 1 in 400 to 1 in 1,000 live births. ADPKD occurs in all 
races with an age-adjusted sex ratio towards male of 1.2 to 1.3.1 The continuous development and 
progression of multiple bilateral renal cysts over decades destroy functional renal parenchyma 
and ultimately lead to a loss of kidney function. The epithelial cells of the cysts are highly 
proliferative and apoptotic, and show planar polarity defects and secretory behaviour.2 In 
ADPKD, end stage renal disease (ESRD) takes place in 50% of affected subjects between their 
50s and 60s with the need for renal replacement therapy (RRT). The systemic character of 
ADPKD implicates renal as well as extra renal manifestations, like hypertension, hepatic cysts, 
intracranial aneurysm and pain, collectively impairing quality of life (QoL).1,3 
 The diagnosis of ADPKD is clinically performed via ultrasound and family history. 
Family history is of help to confirm the diagnosis of ADPKD. However, positive family history 
may be absent in up to 40% of patients, attributable to undiscovered ADPKD in patients’ first 
grade relatives.4 Age specific criteria for ultrasound diagnosis are applied to identify patients at 
risk for PKD1.5 Genetic testing will confirm diagnosis with distinction of PKD1 and PKD2 
mutation. !!!
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Genetics 
 Two genes are causative for ADPKD. PKD1, located on chromosome 16p13.3, accounts 
for 85% of all cases. The remaining 15% are caused by mutations in the PKD2 gene, located at 
chromosome 4q21. Approximately 1% of all ADPKD cases are neither linked to either PKD1 nor 
PKD2 mutations, suggesting the involvement of at least one, so far unindentified other gene.6 De 
novo mutations account for 2 to 5% of ADPKD cases.7 
 Polycystin 1 (PC1), a large complex cell surface glycoprotein is encoded by PKD1. PC1 
contains 4,300 amino acids and a large extracellular domain that supports protein-carbohydrate 
and protein-protein interactions. The structure of PC1 with its 11 transmembrane domains and 
short intracytoplasmic C-terminus contains a G-protein coupled domain and a coiled-coil domain, 
for interacting as receptor and mediating cell-cell and cell-matrix interactions. The PKD1 gene 
includes 46 exons with a 52 kb genomic segment.2 The function of PC1 is not fully elucidated to 
date. 
 PKD2, with its 69 kb genomic region and 15 exons, encodes polycystin 2 (PC2), which is 
involved in cellular calcium signalling.6,7 The 968 amino acid containing protein PC2, also 
named transient receptor potential channel 2 (TRPP2), contains a cilium-targeting motif in the N-
terminus. The C-terminus is involved in protein-protein interactions containing a calcium-binding 
motif and a coiled-coil domain.  
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Figure 1: Predicted structure and topology of polycystin 1 and polycystin 2.8 
 
 The activity of PC2 is regulated by PC1.2 PC1 and PC2 form a heteromeric complex by 
their C-termini at the cell surface of the primary cilium, acting as flow sensor in the primary 
cilium. Beside the cilium, PC1 and PC2 are localized in the plasma membrane and in the 
endoplasmatic reticulum. Decreased expression of PC1 and PC2 results in increased cell 
proliferation and apoptosis, disturbed planar cell polarity and extracellular matrix alterations. 
Furthermore, a change in salt and fluid transport from a reabsorptive to a secretory pattern 
occurs.2,8,9 The genotype is reflected in phenotypic heterogeneity in ADPKD. PKD1 mutations 
are associated with a more severe disease course with reaching ESRD approximately 20 years 
earlier compared with PKD2 mutations.1 
 
Progress 
 In absence of family history, ADPKD often remains unrecognized until the appearance of 
clinically evident symptoms. Cyst growth is already seen in foetusses.10 Early ADPKD symptoms 
occur in 2 to 5% of new-borns and can be mistaken for ARPKD.4,11 A substantial intra-familial 
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variability of ESRD onset within each genotype adverts to the influence of environmental factors, 
epigenetic mechanism, and other modifying genes in the pathogenesis of ADPKD.12 The disease 
commonly becomes clinical evident in the 3rd decade of life.  
 
Renal Manifestation 
 The exponential increase of total kidney volume is determined by continuous cyst growth. 
The annual average kidney growth in early disease is 5.3% ± 4.0% with an estimated doubling of 
kidney volume over 8 years.13 This increase in kidney volume is quantifiable in small periods of 
6 month.14 Cysts originate from all parts of the nephron, but only about 1% of the nephrons 
develop cysts.15 Due to the capacity of the remaining nephrons to hyperfiltrate, kidney function 
stays stable over decades. Once the majority of renal parenchyma has been replaced by cystic 
tissue, kidney function declines. According to estimated glomerular filtration rate (eGFR), stages  
 
Table 1: Stages of CKD by estimated glomerular filtration rate. Adapted from16 
CKD stages Description GFR [ml/min/1.73m2] 
1 Normal to high ≥90 
2 Mildly decreased 60 –89 
3a Mildly to moderately decreased 45 – 59 
3b Moderately to severely decreased 30 – 44 
4 Severely decreased 15 – 29 
5 Kidney failure <15 
 
 Hypertension, blood pressure above 140/90 mmHg, is a common comorbidity in 75 to 
85% of ADPKD patients. It is a major contributor to cardiovascular mortality and associated with 
faster progression to ESRD. Increasing evidence points to the activation of the renin-angiotensin-
aldosteron-system (RAAS) being responsible for the pathophysiology of hypertension.17 The 
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stretch and compression of the vasculature by cysts cause relative ischemia, probably leading to 
increased renin release.1 Untreated hypertension is a major contributor to cardiovascular disease 
and is a major cause of death in ADPKD.  
 Nephrolithiasis, urinary tract infections (UTI) and gross hematuria are common and 
frequent renal morbidities in the course of ADPKD.18-20 16 to 25% of ADPKD patients 
experience at least one episode of kidney stones, due to metabolic abnormalities or stasis by 
virtue of increased pressure on collecting ducts caused by multiple cysts.18,21 
 60% of adult ADPKD patients report pain which is associated with the aforementioned 
co-morbidities.1 The expansion of cysts and the compression of nearby tissue in kidney and liver 
are causes for pain, beside increased lumbar lordosis, traction of the renal pedicle and 
exaggerated pelvic tilt.22 Chronically pain impairs patients quality of life (QoL). Predictors for 
accelerated disease progression are genotype, hypertension, hematuria, urinary sodium excretion, 
and urine concentration impairment.10 
 
Extrarenal Manifestation ! Hepatic cysts are a common extrarenal manifestation in ADPKD and more pronounced in 
female.23 Associated with both genotypes, liver cysts are usually not impairing liver function. 
The excessive proliferation and dilatation of biliary ducts and peribiliary glands cause dispnea, 
create an early sense of satiety or cause oesophageal reflux thereby further impairing patients 
QoL. The impact on patients QoL justifies interventions to retard liver expansion.24 In contrast to 
the kidney, cysts are not fully accounting for hepatomegaly. Increased liver parenchymal volume 
of ADPKD patients compared with healthy volunteers, hyperplasia and hypertrophy of 
hepatocytes have been investigated in mice with reduced PKD1 expression.25 
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 Echocardiography reveals valvular abnormalities in 25% of the patients.1 Left ventricular 
hypertrophy (LVH) occurs early and may include traditional risk factors like hypertension but 
also disease specific factors like fibroblast growth factor 23 (FGF23) but the causative 
mechanisms are incompletely understood.17,26,27 The prevalence of intracranial aneurysms with 
potential severe outcome is higher in patients with ADPKD compared with healthy controls 
(5.8% versus 2.8%).21 Supposing a positive family history, patients are recommended to undergo 
an angiographic screening per decade.28 
 Extra renal manifestations further include prostate cysts, sperm abnormalities, umbilical 
hernias, pancreatic cysts and colic diverticulosis and others.29-32 Advanced kidney disease is 
associated with a severe dysregulation of endocrine, metabolic and hematological systems. 
Dysregulation of mineral metabolism presents as aberrations of calcium, phosphate, parathyroid 
hormone, FGF23, klotho and vitamin D metabolism.33 !
Treatment 
Standard Care 
 Until recently no disease modifying treatment was available. The vasopressin 2 receptor 
antagonist Tolvaptan has been recently approved in Japan, Canada and Europe. This will be the 
first medication for the treatment of ADPKD. So far patients are treated according to standard 
medical care with the focus on comorbidities of ADPKD. 
 Early onset of hypertension may lead to an earlier onset of ESRD and blood pressure 
management should begin early in disease course.34 A rigorous blood pressure control (95/60 to 
110/75 mmHg) significantly decreases kidney enlargement but did not affect kidney function as 
shown in the HALT-PKD trial.17 
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 Increased water intake reduces the levels of AVP and causes lower urine osmolality. 
Lower levels of AVP result in lower renal 3’-5’-cyclic adenosine monophosphate (cAMP) levels, 
which ameliorates disease progression through reducing fluid secretion and mitogenesis in 
cysts.10,35 
 There are several lifestyle recommendation that are mainly opinion-based.36 It is 
recommended to restrict or eliminate the consumption of caffeine containing beverages and 
foods.37 Methylxanthines like caffeine inhibit phosphodiesterases that break down cAMP and 
therefore intracellular basal levels of cAMP in renal epithelial cells increase.38 
 Once reaching ESRD, patients need to undergo renal replacement therapy (RRT), 
transplantation or dialysis. 
 
New Therapeutic Targets 
 During the last three decades increasing knowledge about the basic pathophysiological 
processes of ADPKD defined novel therapeutic targets. Strategies for new therapeutic treatments 
focus on the inhibition of cell proliferation and fluid secretion into cysts as well as the reduction 
of intracellular cAMP.  
 
Tolvaptan  ! The antidiuretic hormone arginine vasopressin and its secondary messenger cAMP 
promote cystic cell proliferation and fluid secretion, as shown in animal models of PKD.39-43 
Abnormal high renal cAMP levels in animal models may be found during the activation of the 
vasopressin receptor pathway. cAMP plays a major role in cystogenesis. The polycystin pathway, 
which is disrupted in ADPKD, is involved in regulation of intracellular calcium. The disruption 
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of the polycystin pathway results in a decreased release of Ca2+ from intracellular stores of renal 
epithelial cells. This stimulates adenylyl cyclase VI and inhibits cAMP-dependent 
phosphodiesterases, resulting in increased levels of intracellular cAMP.39  
 Tolvaptan is a selective vasopressin 2 receptor antagonist and was originally approved for 
the therapy of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and cardiac 
disease induced edema.44 The TEMPO 3:4 trail in ADPKD patients with moderately reduced 
eGFR ≥ 60 ml per min per 1.73m2 and a kidney volume ≥ 750 cm3 showed a reduced annual 
growth rate under tolvaptan treatment compared with placebo group (2.8% versus 5.5% per 
year).45  !
mTOR Inhibitors 
 Inhibitors of the mammalian target of rapamycin (mTOR) block cystogenesis in animal 
models of PKD.46,47 The Ser/Thr kinase mTOR is involved in the regulation of cell proliferation, 
cell growth and cell cycle progression.46,48 The ribosomal protein S6 kinase is a downstream 
target of the mTOR complex, composed of mTORC1 and mTORC2, and regulates translational 
initiation of cell proliferation and growth.48 Increased levels of S6 kinase and activation of the 
mTOR pathway has been found in animal models of PKD.46 
 The mTOR inhibitor Sirolimus has strong anti-proliferate properties and is clinically used 
to prevent organ rejection following renal transplantation.49 Despite the promising results from 
preclinical studies, mTOR inhibition with Sirolimus and Everolimus failed to show an effect on 
kidney function and disease progression in APDKD patients.50,51 
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Long Acting Somatostatin Analogue 
 The effect of somatostatins to reduce renal and hepatic volume in ADPKD has been found 
by chance during the treatment for neuroendocrine tumors. The biological somatostatin peptide is 
secreted by pancreatic islets, the gastrointestinal tract, nervous system and thyroid gland. Its 
receptor type 2 (SST2) is expressed in liver and kidney, where it regulates cAMP levels, thereby 
influencing cell growth and proliferation. The treatment with the long acting somatostatin 
analogues Octreotid and Lanreotid showed in three studies with small groups of patients with 
ADPKD and polycystic liver disease (PLD) decelerated liver growth rates in patients with 
ADPKD and polycystic liver disease.52-54 In these studies liver volume decreased only by 3 to 5% 
with an initial liver volume of 4,400 to 5,500 cm3. GFR was not affected by this treatment. The 
investigators of the multi-centre single-blind randomized ALADIN trial demonstrated a 
significant reduction of annual kidney growth rate in 38 ADPKD patients treated with long acting 
somatostatin analogues compared with placebo at one year of treatment. Unfortunately, growth 
rate was similar in both groups at three year follow up.52 Still, adequately powered studies are 
needed to assess the efficacy of somatostatin analogues for ADPKD.44 !
Preclinical studies  
 Several substances have been tested in preclinical studies to retard PKD progression. 
Roscovitine, a cycline dependent kinase inhibitor, showed promising results in inhibition of 
cystogenesis and improvement of renal function in animal models.55 Inhibitors of the cystic 
fibrosis transmembrane conductance regulator (CFTR) retarded cyst growth in a PKD animal 
model. TRAM-34, an intermediate-conductance inhibitor of Ca2+-activated K+-channel, inhibits 
cyst growth in ADPKD cells.56,57 
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Need for observational studies 
 The natural course of ADPKD with strong inter- and intrafamilal onset of ESRD and the 
long clinically silent phase make it difficult to identify patients that will benefit most from 
upcoming therapies. Increasing basic knowledge of ADPKD has led to the identification of 
multiple novel targets in pre-clinical studies as described before. Once, these substances become 
available, the question has to be answered which patients to select for treatment. The 
identification of surrogate markers to assess disease severity and risk of progression and to 
monitor the effect of interventions on the course of disease remains an important goal and is an 
unmet medical need. The nature of observational studies to observe and to follow the patients 
over a long period makes it possible to evaluate markers of early disease progression and to 
identify patients with faster disease progression. Fast progressing patients at early disease stage 
will benefit most from a medical intervention. Observational studies, like CRISP and EuroCYST 
in ADPKD are extremely valuable and will add important results for the understanding of the 
pathogenesis and characteristics of ADPKD.13,58 
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Biomarkers 
Functional markers versus markers of disease  ! The National Institutes of Health Definition Working Group defines a biomarker as an 
objectively measurable indicator of normal biological and/or pathological processes, or 
pharmacological response to a therapeutic intervention.59,60 Biomarkers help to define disease 
states in a certain condition, to assess prognosis, to predict risk, and to quantify the effect of a 
pharmacological approach (figure 2). Thereby they can be of biochemical origin and are 
measurable in biological media such as human tissue, cells or fluid.61 Type 0 biomarkers reflect 
the natural history of a disease correlating with clinical indices whereas biomarkers of type 1 
capture the effect of an intervention.62 In clinical ADPKD studies the effect of an intervention or 
the assessment of patients at risk is reflected most valuable with clinical end points. The 
achievement of hard endpoints, like death, stroke or ESRD in clinical studies is a time and cost 
intensive endeavour and often not practical. Results may be delivered with delay for the study 
population of impending need.61 Therefore substitutes for clinical endpoints are used to assess the 
effect of an intervention or to assess patients at risk for disease progression. These surrogate 
markers are surrogates for impracticable clinically meaningful endpoints.59 
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Figure 2: Disease pathway and potential impact of biomarkers.63  
 
 A major concern in the application of biomarkers is the inter- and intraindividual 
variability. To monitor patients with a chronic disease longitudinally tight intraindividual 
variability of the biomarker is crucial. In contrast, group variability is a desired outcome in 
studies. Considering possible variations in studies can prevent misclassification of the patients. 
Validity and reliability are crucial for obtaining precise results.63 
 
Biomarkers in ADPKD  
 Biomarkers of disease identify patients at risk, reflect the natural history of the disease 
and can be targets for clinical trials. The interest in reliable biomarkers in the field of nephrology 
is increasing and many potential markers have been studied in conditions, like CKD and acute 
kidney injury (AKI).64 In ADPKD, biomarkers should identify and quantify pathological 
processes and should reflect specific renal glomerular and tubular regions. The extent of renal 
damage can be assessed by markers derived from blood, urine and biopsy specimens as well as 
from imaging procedures and DNA analysis. The advantage of urine as specimen for assessment 
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of biomarkers is its easy accessibility, with preferably low burden for the patient. Furthermore, 
urine is relatively thermodynamically stable, allowing easier handling during analysis.65 In the 
following section different biomarkers of importance in ADPKD will be discussed. 
 
Hematuria 
 Early clinical symptoms include symptomatic or asymptomatic hematuria in children and 
adults affected with ADPKD.10,66,67 In CKD, hematuria is commonly of glomerular origin, caused 
by defects of the glomerular basement membrane, whereas hematuria in ADPKD is of tubular 
origin.68 Macrohematuria is the visible presence of red blood cells in urine and occurs in 30 to 
50% of ADPKD patients. In these patients, macrohematuria occurs frequently and 25% of 
ADPKD patients report more than six aematuric episodes during disease course.69,70 
 The underlying causes for this co-morbidity are cyst hemorrhages into the renal pelvis, the 
rupture of cyst lining vessels due to overactive vascular endothelial growth factor resulting in 
enhanced angiogenesis in the kidney.10,71 Further reasons are UTI, nephrolithiasis, 
glomerulonephritis, artiovenous fistula, trauma and tumors.72 In clinical routine the absence of a 
benign cause and infection distinguish between glomerular and non-glomerular cause. Hematuria 
is a risk factor for an accelerated disease progression in ADPKD and episodes of macrohematuria 
are associated with increased renal volume and hypertension.13,69,73-76 Early and recurrent 
episodes are associated with more severe disease course and worse renal survival.9,71,77 
 Microscopic hematuria is rarely reported in ADPKD and often asymptomatic. The cut off 
for microscopic evaluation differs between laboratories and is between more than 2 to more than 
5 erythrocytes per high power field. The absence of routine assessment makes microhematuria 
often an incidental finding.78 The prevalence of microhematuria in the general population ranges 
between 0.2 and 21%, depending on age and sex, follow up time and number of participants in 
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the study population.79 A large study in young CKD patients in Israel revealed persistent 
microhematuria in 0.3% during a 22 years follow-up. Of those, 0.7% developed ESRD compared 
with 0.04% of CKD patients without persistent microhematuria.80 Hemoglobin from hematuria 
episodes in the tubular system may by itself be a risk factor for disease progression. Free 
hemoglobin in the tubular system promotes reactive oxygen species and may induce renal 
ischemia. Uptake of hemoglobin into the tubular cell increases hydroxyl radicals, apoptosis and 
secretion of cytokines, contributing to inflammatory responses.68 !
Albuminuria 
 Albuminuria is a well-known marker for glomerular permeability and a predictor for 
kidney function decline. Urinary excretion of albumin is associated with CKD progression, 
decreasing eGFR, myocardial infarction and mortality.81-84 The advantage of albuminuria as 
valuable marker is that its urinary appearance preceedes a change of other established markers of 
kidney function, like creatinine. It is produced and secreted by hepatocytes and is present in the 
plasma of all mammals. As the most abundant plasma protein it represents 60% of the total 
plasma protein. The urinary excretion in health is below 30 mg per 24 h. An excretion of 30 to 
300 mg albumin per 24 h is classified as microalbuminuria. Macroalbuminuria reflects an 
excretion of 300 mg to 3 g albumin per day. Nephritic range albuminuria describes urinary 
excretion above 3 g per 24h.81 One important function of the 69 kDa protein is the maintenance 
of oncotic pressure between plasma and interstitial space.85 Furthermore it is a transport protein 
for endogenous and exogenous molecules (amino acids, fatty acids, hormones, metabolites, pro-
inflammatory substances, drugs etc.).86,87 Thus a loss of albumin and its ligands via urine should 
be prevented. The radius and negative charge of albumin restrict filtration in the Bowmans’ 
capsule. Hence, the fractional excretion of albumin is about 0.05 to 0.1%.85 Quantitatively 
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reabsorption of albumin in the proximal convoluted tubule takes place via absorptive receptor-
mediated endocytosis. Thus, albuminuria can occur from glomerular or tubular processes.86 ! Albuminuria is common in CKD and usually preceedes the fall in GFR. Increased 
excretion of albumin in ADKD is associated with TKV, renal blood flow and GFR, myocardial 
infarction and mortality.81-83,88,89 Steeper declines in kidney function are associated with higher 
levels of proteinuria.34 Albuminuria is also observed in children with postnatal diagnosis of 
ADPKD.90 The assessment of microalbuminuria is an accurate method to detect patients at risk 
for cardiovascular morbiditiy.91 The albumin-to-creatinine ratio was added to the CKD stages by 
the Kidney Disease: Improving Global Outcomes (KDIGO) in 2012.92 
 
Neutrophil gelatinase-associated lipocalin-1 (NGAL) 
 The 25 kDa protein NGAL is expressed in kidney, liver, stomach, trachea, colon, lung, 
salivary gland, and epithelial and vascular cells.82,93,94 As a member of the lipocalin superfamily, 
NGAL forms calyces to bind low molecular weight molecules, like bacterial siderophores.95 
NGAL can either eliminate iron or deliver it intracellularly for iron-depending enzymes. Holo-
NGAL facilitates the cytoplasmic iron supply by binding and transporting iron particles into the 
cells, where it activates iron-dependent pathways through the release of its siderophore-iron 
complex in the cytoplasmic region.96 In contrast, internalized Apo-NGAL carries iron to the 
extracellular space, leading to a depletion of intracellular iron.97 The cell activity of NGAL is 
mediated by the brain type cation transporter 24p3R and the megalin multiscavenger complex. In 
the presence of NGAL the enterocholin-iron-complex of gram-negative bacteria binds to it, 
thereby preventing iron transfer to bacteria. NGAL deficient mice are more susceptible to 
infections with gram-negative bacteria compared to wildtype mice.98 
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 NGAL is almost completely reabsorbed in the proximal tubule by endocytosis and under 
physiological conditions only small amounts of NGAL are excreted via urine.97 During renal 
injury NGAL expression is increased in renal distal epithelial cells and urinary excretion rises 
before creatinine rise is observed.99 Elevated levels of NGAL are predictors for disease 
progression and have been reported in AKI and CKD.89,97,100,101 Levels are massively increased 
following nephrotoxic and ischemic defects in the proximal and distal tubules and can be 
measured very sensitively in blood and urine.82 
 Rising urinary excretion of NGAL is associated with TKV, kidney function worsening 
within one year and accelerated progression to ESRD in ADPKD.82,89,99,101,102 Furthermore, the 
number and size of cysts was positively associated with urinary NGAL, independently of renal 
function.103 
 
Kidney Injury Molecule-1 (KIM-1) 
 Under physiological conditions the kidney injury molecule 1 (KIM-1) is absent from 
human urine. It was discovered while studying molecules involved in AKI and it is the founding 
member of the immunoglobulin and mucin-containing molecule 1 family (TIM-1). It is 
exclusively expressed in the cilium of proximal tubular cells.104 Secretion takes place during 
proliferation and dedifferentiation and the 90 kDa ectodomain is cleaved into urine under the 
control of MAP kinases.105 The MAP kinase-signalling pathway is activated by cell stress. KIM-1 
is a phosphatidylserine receptor, mediating phagocytosis of necrotic cells by acting as apoptotic 
factor.93,105 It facilitates repair by removing exosomes and dying cells in the proximal tubular 
cell. Immunological studies show that ligand concentration determines a stimulatory or inhibitory 
effect on KIM-1.105 So, the KIM-1 receptor seems to fulfil two different functions: first its role in 
repair processes in the proximal tubular cell and second, its action in inflammation by attracting 
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macrophages and fibroblasts to injured epithelial cells.106,107 The upregulation of KIM-1 has been 
observed in many states of kidney injury and chronically KIM-1 expression leads to chronic 
kidney failure.108  
 Since KIM-1 is located at the cilium it may interact with TRPP2 and therefore play a role 
in ADPKD. In fact, KIM-1 expression was found in subsets of cysts of the PKD1 mouse model, 
whereas wildtype mice did not express KIM-1 in the kidney.109,110 The expression was associated 
with a loss of polarity, decreasing complexity and decreased levels of the Na-K-ATPase. KIM-1 
is associated with the N-terminus of TRPP2 but fails to interact in PKD. Also, mutations in KIM-
1, lacking Y350, may interrupt the flow induced calcium increase. So far, knockdown of KIM-1 
in epithelial tubule cells (MDCK) was not sufficient to prove the effect on calcium flow.104 
 Urinary KIM-1 is increased in patients with AKI, CKD and is associated with renal graft 
loss and ESRD.89,93,111-114 Even so studies investigating KIM-1 in ADPKD are meagre, urinary 
KIM-1 excretion seems to be increased during the course of ADPKD. A positive association of 
KIM-1 levels in 24 hour urinary samples with TKV, independent of albuminuria in ADPKD was 
reported by Meijer et al.89 Also Kühn et al. reported an increase in KIM-1 levels in PKD 
patients.110 
 
Uromodulin (Tamm-Horsfall Protein) 
 Uromodulin (Tamm-Horsfall Protein) is the most abundant protein in human urine and a 
major component of urinary casts. The daily excretion is about 20 to 100 mg per day in healthy 
persons, depending on diet, urine volume and physical activity.115-118 The glycosyl-
phosphatidylinositol (GPI) anchored protein is exclusively produced in and secreted via the 
apical plasma membrane of the epithelial cells of the thick ascending limb (TAL) of the Loop of 
Henle, a tubule segment with high electrolyte permeability. Uromodulin is also localized in cells 
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of the early distal convoluted tubule.118 It is released into urine by proteolytic cleavage from the 
luminal surface of the TAL, by yet unknown proteases.119,120 The 80 to 90 kDa protein contains 
616 amino acids.115,116,121 The clear physiological roles of uromodulin are still elusive. Evidence 
suggests that uromodulin prevents UTI and nephrolithiasis.122 Uromodulin averts UTI by binding 
to uropathogenic Escherichia coli via its 8 sites of N-glycosylation. The preventive activity of 
nephrolithiasis is attributable to prevention of calcium oxalate crystal aggregation through its 
epidermal growth factor domains with calcium-binding domains. Uromodulin-KO mice with 
absent uromodulin expression and excretion are more susceptible to UTI due to binding of 
uropathogenic E.coli, preventing the binding to uroplakin receptors of the urothelium 
surface.123,124 Mutations in the UMOD gene, located on chromosome 16, cause lower levels of 
urinary uromodulin excretion in a gender- and sex-independent manner and independent of 
severity of renal failure. Interestingly, subjects with decreased uromodulin excretion do not 
present UTI or nephrolithiasis more frequently compared with healthy.116 This may be explained 
by the fact that humans with UMOD mutation still excrete small amounts of uromodulin via urine 
whereas uromodulin KO mice did not secrete uromodulin at all.123 Also in familial juvenile 
hyperucemic nephropathy (FJHN) the urinary excretion of uromodulin is diminished. In contrast 
to decreased urinary expression in this disease setting the expression is increased and mutated 
uromodulin accumulates in the renal tubules.125 There is increasing evidence that the protein 
regulates the sodium-potassium-chloride transporter (NKCC2) and the renal outer medullary 
potassium channel (ROMK) in the TAL.122 As shown in experiments, ROMK2 channel delivery 
to the plasma membrane is increased by uromodulin expression. The role of uromodulin in innate 
immunity has been deduced from its interaction with parts of the immune system as response to 
nephron damaging conditions.115 
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 The current scientific state of knowledge reveals a decreasing urinary uromodulin 
excretion and is correlated with eGFR in different conditions of kidney disease, including 
ADPKD.119 Decreasing levels of uromodulin in urine of CKD patients, not presenting UMOD 
mutation, may be caused by a reduced number of uromodulin secreting cells attributable to tubule 
damage.118,126,127 This evidence suggested to study the excretion of of uromodulin as biomarker 
for CKD. Urinary uromodulin levels in ADPKD patients have been investigated for the first time 
by us. 
 
Clara Cell Protein 16 (CC16) 
 Tubular markers reflect the secretory and reabsorptive dysfunction of the tubule system of 
the kidney. Traditionally, analysis of cumulative proteinuria gives broad information 
predominantly about the glomerular state. Changes in specific tubular parts are of high predictive 
value. Low molecular weight proteins (LMWP) (13 to 33 kDa), like CC16, display a broad 
functional spectrum.128-130 
 The homodimeric CC16 protein was first isolated by Dakopatts in the 1980s and is 
predominantly expressed in human non-ciliated bronchial Clara cells and to a lower extent in 
nose mucosal epithelial cells, endometrium and in foetal kidney.131,132 Its expression in the lung is 
induced during cell differentiation and diminished by toxic pulmonary agents.133 Secretion into 
the air spaces of the respiratory tract is followed by passive diffusion into plasma. The 15.8 kDa 
protein has been studied in inflammatory diseases, where serum CC16 serves as a marker for 
pulmonary damage. Animal and human studies report increased serum CC16 levels following 
exposure to pulmonary toxicants, like cigarette smoke. Still, its precise physiological function is 
not clear. It is involved in bronchial tissue repair and protection from respiratory tract 
inflammation, by inhibiting phospholipase A, the enzyme responsible for production of 
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prostaglandins and leukotrienes, and for interferon (IFN)-γ production and activity.132 The high 
interindividual, diurnal and gender variability of human serum CC16 remain unexplained so far. 
Postrenal secretion from prostate decreases its specificity in men.129,134 
 CC16 is freely filtered in the glomerulus, reabsorbed in the proximal tubule and excreted 
only in small amounts in urine under physiological conditions.129,130,134 The reabsorption in the 
proximal tubule will likely take place via cubilin-megalin mediated endocytosis by binding of 
CC16 to cubilin, as indicated by animal studies.133,135 As kidney function decreases, urinary 
CC16 excretion increases. Impaired tubular integrity cause elevated urinary excretion of CC16, 
possibly by destruction of the endocytosis machinery due to impaired function and morphology 
of the proximal tubule.133 
 The properties of CC16 would per se qualify as biomarker of proximal tubular injury, due 
to its stability in urine, its sensitivity and its anionic character. Urinary CC16 levels have so far 
not been reported in ADPKD and it needs to be evaluated whether or not CC16 is able to assess 
patients’ disease state in ADPKD.  
 
Imaging as a Marker  
 ADPKD is characterized by continuous kidney enlargement due to growth of cysts in 
medulla and cortex.136 Cystogenesis starts early, is continuous and changes in TKV can be 
measured in short 6-month intervals.14 TKV is associated with cyst growth and will be multiply 
the healthy volume of 150 ml during disease course.137 As commonly observed volume increases 
equally in both kidneys despite heterogeneity in cyst size.13 TKV is associated with pain, 
hypertension, gross hematuria, and proteinuria and is now accepted by researchers as prognostic 
biomarker and used as endpoint in clinical studies investigating new medical treatments in 
ADPKD.138 Kidney volume is inversely correlated to eGFR. Kidney volume growths with an 
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annual growth rate of 5.3% ± 4.0% in early disease stage.137 Height adjusted total kidney volume 
(htTKV) of 600 cm3 per m predicts the progression to CKD stage 3 within 8 years.139 Magnetic 
resonance imaging is the gold standard in imaging procedures and can precisely and reproducible 
detect small cysts without application of contrast media.138 Still, kidney imaging using MR-
techniques are not in clinical routine in all European countries and not available to all patients. 
Imaging and volume quantification requires expertise, is technically demanding and expensive. 
The quality of the images relies on patient complicance and on specific parameters, like 
sequences and slice thickness.139 Additionally, volume quantification using stereological 
approaches is time consuming, since it has to be done manually, tracing each slide, which are 
usually 30 to 40 slices with a thickness of 3 mm per slice, of an MRI to evaluate total kidney 
volume. New approaches like the mid-slice area measurement seem to be precise to estimate total 
kidney volume in clinical setting while saving time.140 
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Hypothesis and Aims 
 During the last decade, much knowledge has been gained about the pathophysiological 
processes in ADPKD. Different medical treatments have been investigated in preclinical and in 
clinical studies.35,46,50-52 Until recently, no medication for treatment of ADPKD was available in 
Europe and clinical practice concentrates on the treatment of co-morbidities aiming to slow down 
disease progression. Specific characteristics of the disease, like the strong inter- and intrafamilar 
variability of disease course remains unexplained as well as the difficulty to assess disease state 
and prognosis. 
 The aim of the EuroCYST Initiative is to contribute to supply the aforementioned unmet 
needs in ADPKD. The design of the study has the potential to identify progression factors and 
biomarkers, and to assess disease stage-specific mortality, morbidity and health-care costs as well 
as Quality of Life. The development and implementation of this large observational international 
study will include 1,100 patients in 13 centres in 10 European countries. This approach is so far 
unique in the field of ADPKD and will harmonize the fragmented research in Europe. 
 The accurate assessment of disease state and progression probability needs easy 
obtainable and reliable biomarker. Kidney function markers like serum creatinine and estimated 
glomerular filtration rate (eGFR) remain stable for long time and their ability to accurately assess 
disease state and to predict progression in the early course of ADPKD is limited. We 
hypothesized that ADPKD patients excrete a specific pattern of urinary proteins that may serve as 
biomarkers to assess disease state and predict disease progression in early disease state. Possible 
markers were evaluated from urine specimens of ADPKD patients to meet the requirements of 
evaluating biomarkers with convenient accessibility and low burden for patients. 
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Abstract 
 
Background. Autosomal dominant polycystic kidney disease (ADPKD) is the most common 
monogenic inherited kidney disease, affecting an estimated 600,000 individuals in Europe. The 
disease is characterized by age-dependent development of a multiple cysts in the kidneys, 
ultimately leading to end-stage renal failure and the need of renal replacement therapy in the 
majority of patients, typically by the fifth or sixth decade of life. The variable disease course, 
even within the same family, remains largely unexplained. Similarly, assessing disease severity 
and prognosis in an individual with ADPKD remains difficult. Epidemiological studies are 
limited due to the fragmentation of ADPKD research in Europe. 
Methods. The EuroCYST initiative aims: (i) to harmonize and develop common standards for 
ADPKD research by starting a collaborative effort to build a network of ADPKD reference 
centres across Europe and (ii) to establish a multicentric observational cohort of ADPKD 
patients. This cohort will be used to study factors influencing the rate of disease progression, 
disease modifiers, disease stage-specific morbidity and mortality, health economic issues and to 
identify predictive disease progression markers. Overall, 1100 patients will be enrolled in 14 
study sites across Europe. Patients will be prospectively followed for at least 3 years. Eligible 
patients will not have participated in a pharmaceutical clinical trial 1 year before enrolment, have 
clinically proven ADPKD, an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m2 
and above, and be able to provide written informed consent. The baseline visit will include a 
physical examination and collection of blood, urine and DNA for biomarker and genetic studies. 
In addition, all participants will be asked to complete questionnaires detailing self-reported health 
status, quality of life, socioeconomic status, health-care use and reproductive planning. All 
subjects will undergo annual follow-up. A magnetic resonance imaging (MRI) scan will be 
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carried out at baseline, and patients are encouraged to undergo a second MRI at 3-year follow-up 
for qualitative and quantitative kidney and liver assessments.  
Conclusions. The ADPKD reference centre network across Europe and the observational cohort 
study will enable European ADPKD researchers to gain insights into the natural history, 
heterogeneity and associated complications of the disease as well as how it affects the lives of 
patients across Europe. 
 
Introduction 
 Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common 
monogenic genetic diseases, affecting ∼1 in 1000 live births, that is ∼600 000 individuals in 
Europe.1 The disease is characterized by the development of multiple cysts in both kidneys and 
by potentially serious complications.136 Disease manifestations impairing quality of life include 
hypertension, chronic pain, intracranial aneurysms, abdominal hernias, hematuria, urinary tract 
infection and kidney stones. Kidney function is often preserved up to the age of 40, but 
subsequently glomerular filtration rate (GFR) decreases and often leads to end-stage renal disease 
(ESRD).141 However, there is wide variability between subjects in disease course, even within 
families that share the same mutation, with some patients never reaching ESRD. 
 ADPKD represents a major burden for public health in the EU, estimated at €1.6 billion 
annually for direct medical costs related to renal replacement therapy.142 This figure is an 
underestimate of the true economic burden, because it does not take into account costs related to 
co-morbidities that frequently occur in patients with impaired kidney function and the loss of 
income generation that is often observed in subjects with later stage kidney disease. Research on 
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prevention of ADPKD-related complications could therefore offer a tremendous return on 
investment. 
 At present, there are no approved disease-modifying treatments available for ADPKD. 
Intensive basic research during the last three decades has contributed to a clearer understanding 
of the basic pathophysiological processes that lead to renal cyst formation in subjects affected by 
ADPKD with definition of novel therapeutic targets.12,143 In animal studies, some of the 
treatments directed at these targets, such as mammalian target of rapamycin (mTOR) inhibitors, 
somatostatin analogues and vasopressin V2-receptor antagonists (V2RA), have shown promising 
results.39,49,144 The clinical trials testing mTOR inhibitors showed no clear impact on disease 
progression.48,50,51 However, recent results from the TEMPO 3:4 and ALADIN trials with the 
V2RA tolvaptan and the somatostatin analogue octreotide have shown an effect on the rates of 
kidney growth and kidney function decline, although long-term treatment safety needs to be 
addressed.35,52 If these therapies become available for clinical use, the pivotal question will be 
which patients to select for treatment. One can hypothesize that ADPKD patients with rapid 
disease progression would benefit most and that treatment should be started at an early stage of 
disease, when the kidneys are more likely to respond to an intervention. Since ADPKD is 
characterized by a long period of stable kidney function, due to compensatory filtration of 
unaffected nephrons, kidney function does not accurately reflect disease severity nor prognosis.13 
Genotype (PKD1 as opposed to PKD2 mutation), male gender and young age at onset of 
hypertension among others associate with faster disease progression in ADPKD.145,146 However, 
the predictive value of these variables is limited and untested in large prospective cohorts. The 
identification of surrogate markers to assess disease severity and risk of progression and to 
monitor the effect of interventions on the course of disease remains an important goal and is an 
unmet medical need. Results of smaller observational studies in ADPKD cohorts, such as CRISP 
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and SUISSE ADPKD, suggest that changes in total kidney volume (TKV) are a predictor of 
subsequent loss of kidney function.147 Magnetic resonance imaging (MRI) has a greater 
sensitivity for the detection of small cysts and allows to measure kidney and liver volume more 
precisely compared with ultrasound. It has been shown that MRI can already reliably detect 
changes in TKV that occur during 6 months of follow-up.14 However, the two interventional 
trials with mTOR inhibitors (refs 50 and 51) did not observe a correlation between total renal 
volume and disease progression (as measured by renal function) questioning whether TKV is a 
suitable surrogate marker for disease progression. In addition, this imaging technique is not 
routine clinical practice for ADPKD subjects in all European countries. Thus, there is a need to 
discover clinical factors or new biomarkers that predict the rate of disease progression. 
 
 Building a large, well-characterized cohort of ADPKD subjects who are followed in a 
longitudinal observational cohort study has the potential to identify progression factors and 
biomarkers, and to assess disease stage-specific mortality, morbidity and health-care costs. This 
knowledge should translate into new diagnostic and therapeutic modalities. This approach 
requires a coordinated multinational action within a network of ADPKD reference centres. The 
EuroCYST initiative aims to build such a network and to establish a large-scale pan-European 
ADPKD cohort serving as a versatile and powerful clinical research platform. Since EuroCYST 
is an academic initiative and not industry driven, free access to information and pseudo-
anonymized biomaterial is ensured, as approved by a research oversight committee. 
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Methods 
 
Objectives 
The primary objectives of the EuroCYST initiative are to: 
. (i)  Build a network of ADPKD reference centres across Europe to provide a translational 
research platform that will enable EU researchers to study the pathogenesis, progression 
factors, morbidity, co-morbidity and health economic issues in ADPKD patients over a 
wide range of kidney function and kidney volume.  
. (ii)  Harmonize and develop common standards for ADPKD-related research by a 
collaborative effort to establish a pan-European ADPKD cohort.  
. (iii)  Harmonize and develop a common ADPKD biobank that includes standardized, 
quality-controlled biomaterials for translational research.  
. (iv)  Create a scaffold to facilitate the integration of current and upcoming technologies to 
ADPKD practice.  
. (v)  Develop evidence-based best practice and need assessments for ADPKD by utilizing 
the outcomes of the EuroCYST initiative and by engaging with relevant stakeholders, 
including patient organizations, clinical and research networks, legislators, policymakers 
and the pharmaceutical industry.  
. (vi)  Serve as an impetus to expand ADPKD training programmes at all levels by 
establishing collaborative and educational liaisons as well as provide standard criteria for 
effective management protocols in ADPKD. 
. (vii) Improve awareness of the relevance of ADPKD including disease-specific 
complications and socioeconomic consequences of the disease among health-care 
professionals and payers. 
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EuroCYST strategy and organization 
 To build a cohort for a longitudinal observational study, 14 centres in 10 countries across 
Europe (Figure 1) will enrol 1100 adult ADPKD patients until the end of 2015. The study is 
funded by a grant of the ERA–EDTA with 1 million Euros. For optimal utilization of the funding, 
centres with expertise in ADPKD and already existing local clinical cohorts have been co-opted, 
so that efforts do not need to focus on recruitment, but can be invested into the establishment of 
the cohort infrastructure, uniform data recording and in-depth analysis of several time and thus 
resource-consuming aspects, such as assisted patient interviews using standardized 
questionnaires. 
 
The enrolment phase started in summer 2013; within 1 year, 250 participants should be included. 
To reach the goal of recruiting 1100 ADPKD patients, each participating ADPKD centre will 
enrol at least 50 and up to a maximum of 100 patients within 2 years to ensure a representative 
distribution of patients across Europe. In a second step, which is beyond the current funding 
period, the cohort could be extended in four ways to: (i) prolong the intended duration of follow-
up to longer than 3 years, (ii) increase the number of patients up to 5000 or more through the 
participation of additional European study centres with a minimum essential dataset, (iii) in- 
crease the information density per patient for specific aspects (e.g. cardiovascular pathology, 
imaging and genetics) or (iv) enrol partners, children and parents of index patients (three-
generation cohort). The participation of additional centres will be possible if appropriate funding 
is obtained. Collaborations at various levels with other research groups to share data and 
biomaterials in order to achieve maximum scientific output will be encouraged. To this end, an 
open and transparent ancillary study policy has been established as part of the study protocol. A 
Steering Committee has been established and is meeting at least twice a year. All decisions by the 
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Steering Committee will be approved on a 75% majority. The establishment of a Central Study 
Coordination Team, which meets on a bi-weekly basis, will ensure rapid and successful project 
implementation and progress. 
 
Figure 1: Location of participating study sites 
 
Eligibility of cohort participants 
Following a consecutive enrolment approach, all patients with ADPKD are considered as 
potentially eligible for the study at pre-screening and will undergo screening for the study. 
Patients aged 18 years and older with an estimated GFR (eGFR) of 30 mL/min/1.73 m2 and 
higher [chronic kidney disease-epidemiology collaboration (CKD-EPI) formula], having a 
diagnosis of ADPKD established based on kidney ultrasound and family history (modified 
Ravine criteria) who have not taken part in a disease-modifying trial at least 1 year or shorter 
before enrolment and are able to provide written informed consent, will be eligible for enrolment 
into the EuroCYST cohort.5,148 Table 1 displays the inclusion and exclusion criteria. Exclusion 
criteria include the likelihood of reaching ESRD within 1 year after enrolment or significant heart 
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disease according to New York Heart Association Stage IV (NYHA Stage IV). A stratification 
strategy based on subjects’ eGFR will avoid a selection bias. Thus, 40 to 60% of included 
patients in each study centre need to have an eGFR of 60 mL/min/1.73 m2 and more. 
 
Study design 
 Patients who meet the inclusion criteria will be invited to participate. All potential 
participants will receive detailed information about the study both verbally and in writing. Local 
ethical committees will approve the study, and the protocol has to fulfil the local regulatory 
requirements and com- plies with Good Clinical Practice (GCP) Guidelines. 
 The study design is shown in Figure 2. At baseline, a detailed medical and ADPKD-
specific assessment will be performed. Family history/pedigree information will be collected, as 
well as information on medical resource use (health-care visits, hospital admission, procedures 
and medication), productivity (employment and absenteeism), information culture within families 
and reproductive planning. The economic and social position, based on income, education and 
occupation, will be assessed. Quality of life will be measured by asking patients to complete the 
KDQOL-SF 1.2™ questionnaire, which includes questions relating to patients’ general health, 
kidney disease and about the effect of the disease on activities of daily living. The protocol will 
also require a physical examination. 
 Follow-up visits will be conducted on an annual basis until the end of study, withdrawal, 
ESRD or death. Follow-up visits will include physical examination, laboratory analyses and 
completing the aforementioned ADPKD-related questionnaires. Participating patients will be 
treated according to current standards of care in routine clinical practice within each country. 
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Figure 6: Study design 
 
Magnetic resonance imaging 
 MRI will be used to measure the different magnitudes and volume parameters of kidney 
and liver. MRI will be performed at the baseline visit and is recommended at 3-year follow-up. 
To obtain high-quality renal and hepatic imaging and maintain consistency between the centres 
participating in the trial, a standardized protocol has been developed. The MRI acquisition 
protocol includes T2 single-shot fast/turbo spin-echo images with fat-saturation, FISP or FIESTA 
3D spoiled gradient echo and T1-3D spoiled gradient echo. Images will be sent using the Picture 
Archiving and Communication System (PACS) to the centres in Zurich and Bergamo, where a 
read out by trained personnel will be performed. Read out of the scans includes whole kidney and 
cyst volume, length, depth, width of the kidney, numbers of cysts and also liver and liver cyst 
volume, using the workstation GE Advantage and the programme volume viewer. 
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Collection and storage of biomaterials 
 The collection of material for biobanking will be conducted at the baseline visit. A 
standard operating procedure (SOP) harmonizes the procedure for sampling, pre-processing and 
storage of biobanking material within the EuroCYST initiative. Serum, plasma and whole blood 
collected on EDTA and spotted, and a 24-h urine sample will be collected, processed and 
aliquoted. They will be shipped in batches to a central biobank storage facility where an 
automated −80°C sample library management system is in place to handle the de-identified 2D 
bar-coded sample vials. The whole blood tubes will be shipped to a central, certified genetic 
laboratory for DNA extraction and storage. The database will be kept separately with a secure 
method to link clinical information to biological samples. 
 
Data management and protection 
 Data collection and data management will be conducted using the web-based data 
management system SecuTrial®, with a data capture, which has been approved by the US Food 
and Drug Administration (FDA) and that fulfils the requirements of the International Conference 
on Harmonization Good Clinical Practice (ICH GCP) and Good Clinical Data Management 
Practices (GCDMP). All electronic case report forms (eCRF) have been implemented into this 
system. Figure 3 shows the different subject areas of the data bank that are reflected in the eCRF. 
Data will be stored for at least 10 years after study termination and a daily back up will be 
performed. The study data are saved on a separate server at the University Hospital Zurich, where 
the clinical trial centre, provider of the data management system, is located. Server access is 
controlled physically and electronically. Each patient will be pseudo-anonymized in a reversible 
manner, and all data introduced into the data management system are coded. Subject 
identification will only be possible at the local study site. Access to the system will be role 
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specific and will only be possible with a unique user-ID and password. High data quality will be 
ensured by performing regular monitoring and reporting of entered data by the coordination 
centre in Zurich. All study site data entered in the eCRF will be checked for completeness and 
plausibility according to predefined rules to draw attention to missing data or errors. Certified 
personnel will monitor the participating centre annually. All patients’ written informed consent 
forms and all study files will be checked for complete- ness, and remain at the individual sites. In 
10% of locally enrolled patients, the source files and eCRFs will be checked for accuracy. In 
addition, frequent communications and annual meetings of reference centre principal 
investigators will ensure study compliance. The centre’s individual results of the study shall be 
owned by the centre. Each centre will provide copies of all results, including but not limited to 
case report forms, to the study coordination centre in Zurich. Owner of the overall data of the 
initiative is the EuroCYST Steering Committee. 
Figure 3: Databank 
 Data Bank EuroCyst
Eligibility
Demographics 
ADPKD HistoryHistory of Diagnosis
Family History
Laboratory Data
Imaging Data
ADPKD Related Complications
Lifestyle DataNoxa
QoL
KDQOL-SF. 1.2/1.3
Family Information/
Planning a Family
Vital Signs
Socioeconomic Data
Biobanking
Adverse Events
Study End
Concomitant
Treatment
Medical History
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Statistical considerations 
 Formal sample size estimation has not been performed for this study. While chronic 
kidney disease cohorts currently aim to enrol at least 3,000 and up to 5,000 patients (CRIC, CKD 
JAC and GCKD) to identify valid associations in subgroups, the common genetic origin in 
APDKD allows important conclusions to be drawn using a smaller sample size.149-151 On the 
other hand, groups of several hundred patients en- rolled in recent randomized controlled trials as 
well as already existing ADPKD cohorts have displayed large variability in the disease 
progression rate as assessed by the change in eGFR rate and TKV despite restrictive inclusion 
and exclusion criteria. Therefore, a larger sample size is required to account for the broader range 
in age and renal function in our cohort. A mixed-effects regression model will be used as the 
modelling framework, with a random effect for each patient (this allows correlation between 
repeated eGFR or TKV measurements in the same patient) and with fixed effects for time with a 
spline structure to model change in eGFR and TKV. 
 
Study outcomes 
 The primary outcome measure of the study will be disease progression, assessed as 
change in eGFR (CKD-EPI) and change in TKV. Secondary outcome measure will be: first, 
onset and severity of ADPKD-related clinical outcomes, such as hypertension, albuminuria, renal 
urine concentrating ability, hematuria, renal pain, cyst infection and nephrolithiasis; secondly, 
self-reported health status, quality of life and pain; and thirdly, health-related resource use and 
ADPKD- related health burden. 
 
Enrolment start 
 The study started enrolling patients in July 2013 and will run for 36 months. 
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Conclusion 
 The fragmentation of cohorts of ADPKD patients in Europe has been an obstacle to a 
better understanding of disease characteristics. Individual efforts in different countries often have 
little inter-changeability and it can be almost impossible to connect detailed clinical information 
held in one database with genetic information or biomaterial sample availability held in other 
databases. Our increasing knowledge of the basic biology of ADPKD has led to the identification 
of multiple novel targets in pre-clinical studies, which will need to be tested in patients. Positive 
results from recent clinical trials also now compel nephrologists to find new ways of risk 
stratification to identify patients at higher risk of disease progression and who may benefit most 
from early intervention. So far, limited data are available addressing patients’ quality of life, 
disease-related health burden, health-care resource use and reproductive planning. Currently, 
available data regarding quality of life for ADPKD patients are limited and often only applicable 
to those on dialysis or transplanted patients.22,152-154 
These issues motivated the EuroCYST initiative, which aims to build an ADPKD reference 
centre network in Europe in order to establish a large pan-European observational cohort that will 
serve as a scaffold and platform enabling researchers to study the pathogenesis, progression 
factors, mortality, co- morbidity as well as health economic issues relevant to ADPKD as a major 
cause of kidney disease. Although there is an interest of the pharmaceutical industry to establish 
ADPKD databases, an independent academic network with a transparent open access policy 
remains essential. The recent establishment of the ERA–EDTA Working Group on Inherited 
Kidney Disorders demonstrates the interest and need for a consolidated pan-European approach 
in the field of inherited kidney diseases at large.155 
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 The establishment of such a cohort has the potential to strengthen European ADPKD 
investigators by harmonizing and standardizing research efforts and will guarantee that current 
and upcoming technologies to study chronic kidney disease can be applied to ADPKD patients 
across Europe. Affected patients and their relatives will benefit from the scientific-medical 
innovations by improved prevention and awareness, treatment of disease-specific complications 
and development of new diagnostic and therapeutic modalities. 
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Summary: ADPKD is a slowly progressing disease with a high inter- and intrafamilial disease 
course. The use of traditional markers like creatinine clearance and eGFR are inappropriate to 
assess disease state. We investigated urinary markers of tubular injury and their association with 
disease burden in ADPKD patients at early disease course. Our results indicate that the 
biomarkers urine osmolality, Urinary Albumin-to-Creatinine Ratio and urinary KIM-1 are 
independently associated with kidney size and should be further investigated to evaluate their 
property to assess disease state at early ADPKD stage.  
! !
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Abstract 
Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by a 
decline in renal function at late disease stage when the majority of functional renal parenchyma is 
replaced by cystic tissue. Thus, kidney function, assessed by estimated glomerular filtration rate 
(eGFR) does not well represent disease burden in early disease. Here, we investigated various 
urinary markers for tubular injury and their association with disease burden in ADPKD patients at 
early disease course. 
Methods:  
ADPKD patients between 18 and 40 years with an eGFR greater or equal to 70 ml per min per 
1.73m2 were eligible for this cross-sectional study. Urinary Neutrophil Gelatinase-Associated 
Lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1), and Uromodulin (UMOD) were 
investigated by Enzyme-Linked Immunosorbent Assay. Clara Cell Protein 16 (CC16) was 
investigated by Latex Immuno Assay. Cryoscopy was performed to assess urine osmolality and 
Urinary Albumin-to-Creatinine Ratio (UACR) was calculated. The association and the predictive 
properties of the markers on eGFR and height adjusted total kidney volume (htTKV) was 
evaluated using multiple regression analysis, incorporating different control variables for 
adjustment. Internal bootstrapping validated the obtained results. 
Results:  
In 139 ADPKD patients (age 31 ± 7 years, mean eGFR of 93 ± 19 ml per min per 1.73 m2) the 
total kidney volume was negatively correlated with eGFR and UMOD and positive associated 
with age, UACR, KIM-1 and urine osmolality after adjustment for possible confounders. Urine 
osmolality and htTKV were also associated with eGFR, whereas no association of CC16, NGAL 
and UMOD with eGFR or htTKV was found. 
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Conclusion: 
UACR and urinary KIM-1 are independently associated with kidney size but not with renal 
function in our study population. Urine osmolality was associated with eGFR and kidney volume 
following adjustment for multiple confounders. Despite statistical significance, the clinical value 
of our results is not yet conceivable. Further studies are needed to evaluate the property of the 
aforementioned biomarkers to assess disease state at early ADPKD stage. 
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Introduction 
 Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common 
inherited kidney diseases. It is characterized by a decline of glomerular filtration rate at advanced 
disease stage and a high inter- and intrafamilial variability in age of end stage renal disease 
(ESRD) onset, implying a challenge to predict individuals’ disease progression. The development 
and continued accretion of cysts, as the most prominent feature in ADPKD, leads to a massive 
enlargement of the kidney and, subsequently, to a loss of its function. So far, no disease 
modifying treatment is available, except the recent approval of the vasopressin V2 receptor 
antagonist Tolvaptan in Japan. Due to glomerular hyperfiltration of the remaining nephrons 
kidney function stays stable over decades. Thus, traditional markers for kidney function like 
serum creatinine and estimated glomerular filtration rate (eGFR) have limited ability to 
accurately assess disease state and to predict progression in the early course of ADPKD. 
Increasing evidence suggests that total kidney volume qualifies as a marker for disease 
progression in ADPKD.1 In fact, the disease state may be reflected more accurately by total 
kidney volume and kidney growth rate than renal functional parameters like eGFR or creatinine 
clearance.89 Total kidney volume can be accurately assessed by Magnetic Resonance Imaging 
(MRI). However MRI derived kidney volume measurements are time and cost intensive, require 
high technical expertise and are not routine clinical practice.  
 Renal cystogenesis in ADPKD is a complex process, characterized by abnormalities in 
tubular cell proliferation, fluid secretion, extracellular matrix formation, and cell polarity.156 The 
process results in an impaired filtration barrier, diminished tubular reabsorption, upregulation of 
tubular proteins and release of markers by recruited inflammatory cells, which can be detected in 
patients’ urine.157 Such markers should have the property to define the patients’ state in a certain 
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disease condition, to predict prognosis, and/or to quantify the effect of a pharmacological 
approach. Mayeux et al defined type 0 biomarkers (diagnostic biomarkers) reflecting the natural 
history and correlating with clinical indices and biomarkers of type 1 (predictive biomarkers) 
capturing the effect of an intervention.63,6 Biomarkers of type 0 that reflect tubular damage and 
have been under investigation in various settings of kidney disease are Neutrophil Gelatinase 
Associated Lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1), Uromodulin (UMOD), Clara 
Cell Protein 16 (CC16) and albuminuria.158 NGAL has been extensively investigated as a 
biomarker, due to its rapid increase in different settings like acute kidney injury, cardiac surgery, 
and kidney transplantation.113,159-162 KIM-1 does not occur in human urine under physiological 
conditions and has been described as progression marker in kidney disease.89 UMOD, the most 
abundant protein in human urine, regulates tubular function and shows protective properties 
against uropathogenic Escherichia coli and nephrolithiasis.115 Decreasing levels of urinary 
UMOD have been reported in various settings of chronic kidney disease (CKD), like 
glomerulonephritis, diabetic nephropathy or tubulointerstitial nephropathy.115,118,163,164 Urinary 
CC16 is consistently associated with defective endocytic uptake by the proximal tubule. CC16 
levels are increased in patients with diabetic and HIV-induced nephropathy, as well as in renal 
Fanconi syndrome.128,165 There is an unmet need to discover new biomarkers that allow an easy 
and non-invasive assessment of ADPKD disease state. Here, we investigated the potential 
properties of the aforementioned markers for assessing disease state by evaluating their 
association with kidney volume and function in patients at early stage of ADPKD.  
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Methods 
Study Subjects 
 Subjects of the well-described SUISSE ADPKD cohort were eligible for enrolment.50,166 
Male and female patients with proven ADPKD diagnosis, examined by kidney ultrasonography, 
according to Ravine criteria, and a positive family history were eligible when aged between 18 
and 40 and presenting with an eGFR greater or equal to 70 ml per min per 1.73m2 as shown in 
Table 1.5 A proof of a mutation in the PKD1 or PKD2 genes was required for enrolment of 
patients without family history (sequencing analysis by Athena Diagnostics Inc., Worcester, MA, 
USA). The study was conducted according to the Declaration of Helsinki and Good Clinical 
Practice Guidelines and was approved by the local ethical board. All patients provided written 
informed consent.  
 
Table 1: Eligibility criteria19 
 
• Age 18 to 40 
• GFR ≥ 70 ml per min per 1.73m2 (Cockcroft-Gault formula) 
! Clinical diagnosis of ADPKD based on kidney imaging 
(modified Ravine criteria) and family history 
! Positive family history for ADPKD 
o patients < 30 years: ≥ 2 cysts in either kidney 
o patients ≥ 30 years: ≥ 2 cysts in each kidney 
• Negative family history for ADPKD cystic kidney disease by 
sonography: proof of a mutation in the PKD1 or PKD2 gene 
• Patient provided written informed consent 
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Study Procedure 
 Subjects were invited to the outpatient clinic at the Division of Nephrology (University 
Hospital Zurich). At study visit the medical history was obtained, including medication and 
ADPKD related complications. Blood pressure measurement was done in duplicate at each arm 
after 5 minutes of rest in sitting position using an oscillometric blood pressure device (Boso-
Medicus, Jungingen, Germany). Hypertension was defined as systolic blood pressure above 140 
mmHg and/or diastolic blood pressure above 90 mmHg or antihypertensive treatment. Fasting 
spot urine samples were collected after voiding the first urine of the day to measure creatinine 
beside the potential biomarkers. Blood samples were centrifuged and aliquoted, according to a 
standardized process, to obtain serum. Serum and spot urine aliquots were stored at –80°C before 
analysis.  
Laboratory Analysis 
 At study visit, serum creatinine was measured according to modified Jaffé method 
traceable to an isotope-dilution mass spectroscopy reference. Estimated GFR was calculated by 
applying the CKD-EPI equation.148 NGAL (BioPorto Diagnostics A/S, Hellerup, Denmark) and 
KIM-1 (R&D Systems Inc., Abingdon, UK) were analyzed using commercially available 
Enzyme-linked Immunosorbent Assays (ELISA) according to manufacturers protocol. UMOD 
was analyzed by a well established ELISA based on a sheep anti-human uromodulin antibody 
(K90071C; Meridian Life Science, Memphis, TN) as the capture antibody, a mouse monoclonal 
anti-human Tamm–Horsfall protein antibody (CL 1032A; Cedarlane Laboratories, Burlington, 
NC) as the primary antibody, and a goat anti-mouse IgG (H+L) horseradish peroxidase–
conjugated protein (172.1011; Bio-Rad Laboratories, Inc., Hercules, CA) as a secondary 
antibody. Human uromodulin (AG 733, stock solution: 100 µg/ml; EMD Millipore, Temecula, 
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CA) was used to establish the standard curve.167 CC16 was analyzed with continuous flow Latex 
Immuno Assay (LIA) and an assayable concentration of CC16 between 0.3 and 40 µg/L.168 
Albuminuria was assessed using Synchron Systems for Microalbumin (Beckman Coulter Inc., 
Brea, California, USA). The urinary albumin-to-creatinine ratio (UACR) was calculated as 
follows: Albumin (mg/dl) x 1/creatinine (mg/dl) x 1000 µg/mg. The analysis of urine osmolality 
was performed by cryoscopy using a freezing point depression Advanced® 2020-BIO Multi-
Sample Osmometer (Advanced Instruments Inc., Norwood, Massachusetts, USA). All samples 
were handled in a uniform way and underwent no freeze-thaw cycle before analyzed in duplicate.  
Magnetic Resonance Imaging 
 Patients underwent magnetic kidney imaging without contrast media according to a 
standardized imaging protocol. The imaging was performed using a Signa Excite HDx system 
(GE Healthcare, Waukesha, WI, USA) and signal perception was obtained with an eight-channel 
antero-posterior-phased array surface coil. Trans-axial sequences consisted of two breathhold T1-
weighted fast-spoiled gradient echo sequences with 3 and 4 mm slice thicknesses. Additionally, a 
trans-axial T2-weighted fast spin echo sequence with respiratory triggering was performed with 3 
mm slice thickness. Right and left kidney volumes were measured and calculated using the 
Advantage Windows workstation (4.4 GE Healthcare, Buc, France). Total kidney volume (TKV) 
was calculated by adding the volume of the left and right kidney. Measurements of renal volume 
were done in a blinded way by two trained and independent observers. The renal hilum and the 
vessels were excluded from renal volume calculation. Variability was calculated as concordance 
correlation coefficients (95% CI) and were 1.000 (0.999–1.000) for intraobserver and 0.996 
(0.995 – 0.999) for interobserver correlations.14 
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Statistical Analysis 
 SAS 9.4 was used for data analysis. A plausibility check of the data preceded the 
statistical analysis. Univariate methods were used to characterize study population. Values are 
given in means with standard deviation. TKV and height adjusted kidney volume (htTKV) are 
reported as median because of a skewed distribution of these parameters. Median is reported with 
interquartile range. 
 Spearman’s correlation coefficient (r) was calculated to describe the correlation between 
biomarkers and eGFR and htTKV. To calculate r, reflecting the relative variance part, all values 
of the parameters are sorted and given a rank.169 A positive r indicates a concordant association, 
whereas a negative r stands for an opposing association.  
  The association of biomarkers with eGFR and htTKV was evaluated by incorporating 
different control variables for adjustment and following a multiple linear regression approach. A 
stratum specific correlation analysis was performed for binary and ordinal variables. Multiple 
regression analysis gives information about importance and size effect of the predictors on the 
response variable, and about the interaction between predictors. Prerequisites, like the 
independence of predictors to each other, were evaluated and fulfilled. The models were 
determined with scatterplots and correlation analysis to verify linearity between outcome variable 
and predictors. Subsequently the regression equation was formed. Adjusted R2 and p-value were 
calculated as statistic measures. R2, the coefficient of determination, reflects the proportion 
response variation that is explained by the predictors.170 Predictor variables were selected 
according to logical considerations and added sequentially to the models. The models were 
compared using the Akaike information criterion (AIC). The AIC is based on the likelihood and 
determines which model is more likely to be correct and comes closer to the “truth”.171 The 
smaller the AIC value the more realistic the model is, assuming, that a robust model predicts the 
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data well containing preferably a low number of predictors meeting the requirement for 
parsimony and avoiding overfitting.172 Bootstrapping was applied to estimate the 2.5th and 97.5th 
percentile confidence intervals for each model. Our dataset was used as a pool from which 500 
new datasets of the same size were randomly drawn with replacement to internally validate our 
model results. 
 
Results 
Demographics 
 Between April 2006 and April 2011 139 ADPKD patients were consecutively enrolled in 
the study. The mean age was 31±7 years and 85 (61%) patients were male. Hypertension was 
present in 82 (78%) patients, and 80 (58%) patients received antihypertensive medication. 
Among those, 50 patients received angiotensin-converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers (ARBs), 16 received diuretics and 14 were treated with calcium 
antagonists. The mean eGFR was 93±19 ml per min per 1.73 m2 and 74 (53%) of the patients had 
an eGFR greater than 90 ml per min per 1.73 m2. The median TKV was 860 cm3 (IQR, 568 to 
1191 cm3) and 52 (37%) patients had a TKV greater than 1000 cm3. The median htTKV was 455 
cm3 (IQR, 17 to 669 cm3). The mean body mass index (BMI) was 24±4 kg per m2, 5 (4%) 
patients had a BMI lower than 18.5 kg per m2 and 53 (38%) patients a BMI above 25 kg per m2 
(Table 2). 
 
 
 
First Author Manuscripts – 59 !
!
Table 2: Characteristics of study cohort 
 ADPKD 
 n = 139 
Age – years 31±7 
Sex – no. (%)  
Female 54 (39) 
Male 85 (61) 
Body mass index – kg per m2 24±4 
BMI <18.5 5 (4) 
BMI 18.5 – 25 81 (58) 
BMI >25 53 (38) 
eGFR – ml per min per 1.73m2  93±19 
CKD stage 1 74 (53) 
CKD stage 2 61 (44) 
CKD stage 3 4 (3) 
TKV – cm3 860 (568 to 1191) 
htTKV – cm3 per m 455 (317 to 669) 
Hypertension – no. (%)*  
Yes 82 (78) 
No 23 (22) 
Blood pressure – mmHg  
     Systolic 131±16 
     Diastolic 83±11 
Antihypertensive Medication - no. (%)  
     ACE / ARB 50 (36) 
     Calcium antagonist 14 (10) 
     Diuretics 16 (12) 
Abbreviations: eGFR – estimated glomerular filtration rate. TKV – total kidney volume, htTKV – height adjusted total kidney 
volume, ACE – angiontensin converting enzyme, ARB – angiotensin II receptor blocker. Values are means ± standard deviation 
and numbers (percentage), TKV and htTKV are reported as median (interquartile range), *total number of observations = 105 
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Analysis of biomarker  
 The results of the urinary parameters osmolality, NGAL, KIM-1, UMOD, UACR and 
CC16 were tabulated for the complete cohort and stratified for eGFR and TKV (Table 3). 
Osmolality was measured in 139 spot urine samples. All other potential biomarkers were 
measured in 132 samples. The median urinary osmolality was 364 mosmol per kg H2O (IQR, 257 
to 533 mosmol per kg H2O). The median values were 9.8 µg per g creatinine (IQR, 5.3 to 23.7 µg 
per g creatinine) for NGAL, 274.6 ng per g creatinine (IQR, 131.3 to 457.3 ng per g creatinine) 
for KIM-1, and 16.3 mg per g creatinine (IQR, 10.2 to 26.7 mg per g creatinine) for UMOD. In 
the whole cohort, UACR was 14.0 mg per g creatinine (IQR, 8.4 to 23.1 mg per g creatinine) and 
the median for CC16 was 2.8 µg per l per g creatinine (IQR, 2.0 to 6.2 µg per l per g creatinine). 
The median of KIM-1 was significantly higher among patients with TKV above 1000 cm3 than 
among patients with TKV lower or equal 1000 cm3. Osmolality, NGAL, UMOD, UACR and 
CC16 were similar among patients with an eGFR above 90 ml per min per 1.73m2 and less or 
equal 90 ml per min per 1.73m2.
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Table 3: Biomarker Analysis 
 n Complete Cohort eGFR >90                          
ml per min per 1.73m2 
eGFR ≤90                              
ml per min per 1.73m2 
TKV ≤1000 cm3 TKV >1000 cm3 
Osmolality – mosmol per kg H2O 139 364 (257 to 533) 377 (266 to 534) 360 (243 to 506) 330 (236 to 497) 417 (332 to 547) 
NGAL – µg per gcreatinine 132 9.8 (5.3 to 23.7) 8.7 (4.7 to 22.8) 11.3 (5.8 to 24.3) 12.5 (5.3 to 24.3) 9.0 (5.3 to 21.3) 
KIM-1 – ng per gcreatinine 132 274.6 (131.3 to 457.3) 272.0 (113.9 to 448.8) 274.6 (161.3 to 479.9) 211.6 (106.4 to 362.5) 391.3 (196.1 to 581.0)* 
UMOD – mg per gcreatinine 132 16.3 (10.2 to 26.7) 18.1 (10.9 to 29.8) 14.8 (9.1 to 25.6) 19.4 (10.7 to 28.5) 13.6 (8.3 to 21.6) 
UACR – mg per gcreatinine 132 14.0 (8.4 to 23.1) 11.6 (6.9 to 21.8) 15.4 (9.9 to 27.2) 12.0 (7.7 to 21.3) 15.2 (10.4 to 31.1) 
CC16 – µg per l per gcreatinine 132 2.8 (2.0 to 6.2) 3.0 (2.0 to 5.9) 2.6 (2.0 to 6.2) 2.6 (2.0 to 4.8) 3.2 (1.7 to 8.9) 
Abbreviations: NGAL – Neutrophil Gelatinase Associated Lipocalin, KIM-1 – Kidney Injury Molecule-1, UMOD – Uromodulin, UACR – Urinary Albumin-to-Creatinine Ratio, CC16 
– Clara Cell Protein 16. Values are reported as median (interquartile range), * p < 0.0
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Correlation of biomarker with indices of disease progression 
 Table 4 shows the correlation of biomarkers with eGFR and TKV. Estimated GFR was 
negatively correlated with TKV (r = -0.44508, p<0.05), htTKV (r = 0.45531, p<0.05), age (r = -
0.51026, p<0.05) and UACR (r = -0.20042, p<0.05). TKV was negatively correlated with eGFR 
(r = -0.44508, p<0.05) and UMOD (r = -0.22771 p<0.05) and positively correlated with age (r = 
0.22493, p<0.05), urinary albumin (r = 0.25524, p<0.05), osmolality (r = 0.1949, p<0.05) and 
KIM-1 (r = 0.32129, p<0.05) (Table 4). Biomarker distribution is shown in figure 1 and 2. 
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Table 4: Spearman Correlation Coefficient r 
 eGFR TKV htTKV Age NGAL OSMOL KIM-1 UMOD UACR CC16 
eGFR 1 -0.44508* -0.45531* -0.51026* -0.06826 0.13563 -0.0867 0.14841 -0.20042* 0.01184 
TKV -0.44508* 1 0.99389* 0.22493* -0.0254 0.1949* 0.32129* -0.22771* 0.25524* 0.12924 
Abbreviations: eGFR – estimated glomerular filtration rate, TKV – total kidney volume, htTKV –height adjusted total kidney volume, NGAL – Neutrophil Gelatinase Associated 
Lipocalin, OSMOL  – Osmolality, UMOD –Uromodulin, KIM-1 –Kidney Injury Molecule-1, UACR – Urinary Albumin-Creatinine-Ratio, CC16 – Clara Cell Protein 16. * p < 0.05 #
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Abbreviations: htTKV – height adjusted total kidney volume, NGAL – Neutrophil Gelatinase Associated Lipocalin, KIM-1 – 
Kidney Injury Molecule-1, UMOD – Uromodulin, UACR – Urinary Albumin-to-Creatinine Ratio, CC16 – Clara Cell Protein 16 
Figure 1: Estimated glomerular filtration rate (eGFR) and parameter distribution 
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Abbreviations: eGFR – estimated glomerular filtration rate, htTKV – height adjusted total kidney volume, NGAL – Neutrophil 
Gelatinase Associated Lipocalin, KIM-1 – Kidney Injury Molecule-1, UMOD – Uromodulin, UACR – Urinary Albumin-to-
Creatinine Ratio, CC16 – Clara Cell Protein 16 #
Figure 2: Total kidney volume (TKV) and parameter distribution 
Regression analysis for htTKV and eGFR as outcome parameter 
 Simple and multiple linear regression analysis were applied to delineate the independent 
associations of urinary biomarkers with eGFR and htTKV. Kidney volume is affected by a 
number of a priori known biological factors, e.g. age, gender, and glomerular filtration rate. 
Predictive variables were chosen in a predefined step-wise approach: In model 1 (Table 5) eGFR 
(β = -0.45968, p<.0001) was selected as a predictor; the term eGFR captures race, age and 
gender. The prognostic power of eGFR to predict htTKV is 20.6% (R2 = 0.2055) with an AIC of -
199.6. Bootstrapping revealed a percentile confidence interval of 0.0987 and 0.3374. 
 The selection of osmolality and UACR to model 1 as independent variables increased the 
R2 to 0.3373 (percentile CI, 0.2306 – 0.4755), and the AIC to -210.7 (Table 6; Model 2). An 
increase of UACR (b = 0.20465, p<.0001) and urine osmolality (b = 0.32114, p<.0001) is 
independently of renal function, race, age, and gender associated with an increase in htTKV. All 
predictors of model 2 are independently predictors of htTKV at an alpha level of 0.1%. Estimated 
GFR has the most predictive power of all 3 variables in this model (β = -0.42435). The 
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standardized estimate β was calculated to evaluate the predictors independently of their 
transformation and their level of measurement.  
 Adjusted R2 of model 3 was 0.3366 after selection of KIM-1, NGAL, UMOD, CC16 to 
eGFR, osmolality and UACR (Table 7). A percentile confidence interval of 0.2866 to 0.5278 was 
obtained in bootstrap validation. Out of the seven aforementioned variables, eGFR, osmolality, 
UACR and KIM-1 are major factors to predict htTKV. In model 3, the variable UACR is the 
second largest predictor variable with a β of 0.30403. Osmolality had a β of 0.21408, and KIM-1 
a β of 0.18993. NGAL, UMOD and CC16 had low β-values and were minor determinants in the 
prognosis of htTKV. In model 3 osmolality, UACR and KIM-1 are positively correlated with 
kidney volume. The AIC of model 3 was -209.9. The additional selection of KIM-1, NGAL, 
UMOD and CC16 did not increase R2 and did not change AIC.  
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Table 5: Simple linear regression height adjusted total kidney volume (transformed to log htTKV) Model 1 
variable Parameter 
estimate b 
p Standardized 
estimate β 
Standard 
Error 
Adjusted 
R2 
AIC 
Intercept 2.20103 <.0001 0 0.1145 0.2055 -199.6 
eGFR1 – ml per min per 1.73m2 -0.00007127 <.0001 -0.45968 0.00001181   
1square root transformed 
 
Table 6: Multiple linear regression height adjusted total kidney volume (transformed to log htTKV) Model 2 
variable Parameter 
estimate b 
p Standardized 
estimate β 
Standard 
Error 
Adjusted 
R2 
AIC 
Intercept -0.29424   0.5704 0 0.51711 0.3373 -210.7 
eGFR1 – ml per min per 1.73m2 -0.00006612 <.0001 -0.42435 0.00001149   
Osmolality2 – mosmol per kg H2O 0.32114 <.0001 0.30774 0.07825   
UACR2 – mg per gcreatinine 0.20465 <.0001  0.31058 0.04985   
1 square root transformed 
2 log transformed 
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Table 7: Multiple linear regression height adjusted total kidney volume (transformed to log htTKV) Model 3 
variable Parameter 
estimate b 
p  Standardized 
estimate β 
Standard 
Error 
Adjusted 
R2 
AIC 
Intercept 0.00847   0.9895 0 0.64145 0.3366 -209.9 
eGFR1 – ml per min per1.73m2 -0.00006259 <.0001 -0.40173 0.00001166   
Osmolality2 – mosmol per kg H2O 0.2234   0.0186 0.21408 0.09366   
UACR2 – mg per gcreatinine 0.20033   0.001 0.30403 0.05951   
KIM-12 – ng per gcreatinine 0.09432   0.0191 0.18993 0.0475   
NGAL2 – µg per gcreatinine -0.05253   0.2709 -0.09574 0.0397   
UMOD2 – mg per gcreatinine -0.04606   0.4653 -0.06085 0.06289   
CC162 – µg per l per gcreatinine -0.00504 0.9212 -0.00794 0.05087   
1 square root transformed 
2 log transformed
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 Subsequently different models were established to predict eGFR. In model 1 (Table 8) 
htTKV and osmolality were added on priory knowledge to predict eGFR. Both variables were 
independently associated with eGFR, and htTKV (β = -0.49803) had a larger association with 
eGFR compared with osmolality (β = 0.22936). The adjusted R2 for this model is 0.2515 
(percentile CI, 0.1588 – 0.3809) and thus approximately 25% of eGFR variation is explained by 
htTKV and osmolality. 
 In model 2 (Table 9) the predicting parameters htTKV, osmolality and UACR account for 
22.09% of eGFR variation with an adjusted R2 of 0.2209. A percentile confidence interval of 
0.1319 to 0.3738 was obtained in bootstrap validation. The predictor htTKV has the largest 
impact on the outcome in this model (β = -0.48736) and osmolality showed the second largest 
value for standardized estimate (β = 0.21857). UACR has a comparably low β.  
 In model 3 (Table 10) the parameters htTKV, osmolality, UACR, NGAL, KIM-1, UMOD 
and CC16 were entered. Height adjusted total kidney volume (β = -0.47261; p<.0001) and 
osmolality (β = -0.27024; p = 0.006) were independently associated with changes of eGFR. The 
additional selection of NGAL, KIM-1, UMOD and CC16 resulted in a stable R2 and AIC. 
Bootstrapping revealed a percentile confidence interval of 0.1674 to 0.4153. 
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Table 8: Multiple linear regression estimated glomerular filtration rate (square root transformed eGFR) Model 1 
variable Parameter 
estimate b 
p Standardized 
estimate β 
Standard 
Error 
Adjusted 
R2 
AIC 
Intercept 4899.70827   0.1014  0 2970.99215 0.2515 2214.2 
htTKV1 – cm3 per m -3212.08387 <.0001 -0.49803 483.52856   
Osmolality1 – mosmol per kg H2O 1549.70316   0.0027  0.22936 506.54097   
1 log transformed 
 
Table 9: Multiple linear regression estimated glomerular filtration rate (transformed to square root eGFR) Model 2 
Variable Parameter 
estimate b 
p Standardized 
estimate 
β 
Standard 
Error 
Adjusted 
R2 
AIC 
Intercept 4899.8604   0.1681  0 3534.68607 0.2209 2104.3 
htTKV1 – cm3 per m -3127.98641 <.0001 -0.48736 543.58333   
Osmolality1 – mosmol per kg H2O 1463.87536   0.0098 0.21857 557.90345   
UACR1 – mg per gcreatinine 100.97551   0.7824  0.02388 364.80352   
1 log transformed 
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Table 10: Multiple linear regression estimated glomerular filtration rate (transformed to square root eGFR) Model 3 
Variable Parameter 
estimate b 
p Standardized  
estimate β 
Standard 
Error 
Adjusted 
R2 
AIC 
Intercept 170.01158   0.9697   0 4465.37589 0.2195 2108.4 
htTKV1 – cm3 per m -3333.33092 <.0001 -0.47261 564.97273   
Osmolality1 – mosmol per kg H2O 1809.95369   0.006 0.27024 646.61622   
UACR1 – mg per gcreatinine 42.27981   0.9224 0.01 432.9461   
NGAL1 – µg per gcreatinine -136.7632   0.6812 -0.03884 332.06115   
KIM-11 – ng per gcreatinine 185.45311   0.5123 0.05818 282.16858   
UMOD1 – mg per gcreatinine 798.52678   0.0675 0.16434 432.84451   
CC161 – µg per l per gcreatinine -138.45145   0.6963 -0.03397 353.90411   
1 log transformed 
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Discussion 
 The cystogenesis in ADPKD replaces functional renal parenchyma and leads to a loss of 
kidney function during patients’ lifespan. Since GFR, a traditional parameter of renal function, 
is not able to accurately assess disease state in the early disease course, the interest in 
establishing urinary biomarkers for ADPKD has increased. In this cross-sectional study, we 
investigated the potential biomarkers osmolality, UACR, NGAL, UMOD, CC16, KIM-1 at a 
single time point in spot urine samples of 139 ADPKD patients with preserved renal function. 
Robust statistical approach demonstrated that urinary KIM-1, urinary osmolality and UACR 
are independently associated with kidney volume in our cohort of ADPKD patients.  
 An increase in urinary KIM-1, that is only fractionally expressed under physiological 
conditions, reflects tubular damage in the proximal S3 tubule segment as shown in acute and 
chronic kidney injury.110 In our study, KIM-1 showed the strongest correlation with TKV. 
Multiple regression analysis revealed an independent correlation of KIM-1 with kidney 
volume, after adjustment for eGFR, osmolality, UACR, NGAL, UMOD, and CC16. In 
contrast, KIM-1 was not associated with renal function in multiple regression analysis 
adjusted for renal volume, osmolality, UACR, NGAL, KIM-1, UMOD, and CC16. KIM-1 
expression was found in murine polycystic kidneys but not in wild type mice, driving the 
hypothesis that ADPKD patients may display higher urinary KIM-1 excretion.110 KIM-1 has 
been identified as novel ciliary molecule. By interacting with the PKD2 Protein Transient 
Receptor Potential Polycystic 2, KIM-1 may be involved in cellular response to changes in 
extracellular fluid flow detected by the cilium.109 To our knowledge urinary KIM-1 levels in 
ADPKD has only been reported once. In a study of Meijer et al increased KIM-1 levels in 24h 
urine samples of ADPKD patients were associated with total kidney volume, adjusted for age, 
gender and albuminuria compared with healthy volunteers.89 In our study, KIM-1 was 
associated with TKV whereas renal function that is stable at early disease stage was not 
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associated with KIM-1. Given the limited available data of KIM-1 in APDKD patients, it is 
not possible to draw a conclusion about the property of KIM-1 as biomarker in early ADPKD.  
 A defect in osmoregulation has been shown in animal models of ADPKD as well as in 
patients.173-175 The impaired capacity of urine concentration is an early manifestation and can 
be observed in children.175,176 With our study we confirm the independent association of 
osmolality and TKV as shown by Ho et al.175 Following multiple adjustments, urine 
osmolality is independently associated with kidney volume and function in our cohort. Hence, 
the assessment of spot urine osmolality may add further information for disease state 
assessment in ADPKD patients at early disease stage.  
 Albuminuria is known as marker for kidney damage for years. Urinary albumin excretion 
is routinely assessed in the diagnosis of renal injury, due its urinary appearance prior to GFR 
decline in different renal diseases. Albuminuria is associated with CKD progression, 
decreasing eGFR, increasing TKV, myocardial infarction and mortality.14,25,81-84 In our study, 
UACR predicts the variation in htTKV but did not qualify as predictor for kidney function. 
 KIM-1, urine osmolality and UACR are independently associated with disease state in 
our study, but no association of NGAL, UMOD and CC16 with kidney volume and function 
at early ADPKD state was found. NGAL has been extensively studied as biomarker in acute 
kidney injury, but only limited data is available reporting NGAL levels in ADPKD.113,159-
162,177 Boligano et al reported markedly increased urinary NGAL levels in ADPKD patients at 
late disease state (eGFR 59 ± 38 ml per minute, Cockcroft-Gault formula) compared with 
healthy volunteers.101 Parikh and colleagues investigated serum and urinary NGAL levels 
over a three year period in participants of the CRISP study, with kidney function comparable 
to our investigated cohort (creatinine clearance >70 mls/min). The majority of subjects 
showed normal to low baseline urinary NGAL levels. Even so the levels increased during the 
First Author Manuscripts – 75 #
#
study period with a drop at second and third year follow up, no association of NGAL quartiles 
with kidney volume and function were seen. Furthermore they showed highly elevated NGAL 
levels in cystic fluid in ADPKD patients compared to urine and serum values of healthy and 
of patients with AKI. The discrepancy of NGAL levels in urine and in cyst fluid may be 
attributable to a missing communication between tubules and detaching cysts in ADPKD.177 
In summary, NGAL levels may increase only in advanced disease and NGAL is not suitable 
to predict outcome at early stage when renal function is maintained.  
 To our knowledge, UMOD and CC16 levels have not been reported in ADPKD so far. In 
our study, no association of UMOD and CC16 with renal function and kidney volume was 
observed. Decreasing levels of urinary UMOD, which is the most abundant protein in human 
urine, have been reported in various settings of CKD.115,118,163,164 Since the absolute values for 
urinary UMOD in our cohort are comparable with the ones reported in various cohorts, one 
could speculate that UMOD excretion decline starts in later stage of ADPKD.126,178 CC16 is 
secreted by bronchial Clara cells and, after filtration, reabsorbed by receptor-mediated 
endocytosis in the early segments of the proximal tubule.165 Hence, all disorders associated 
with defective proximal tubule endocytosis lead to the urinary loss of CC16.179 The described 
lack of association of CC16 with kidney volume in contrast to KIM-1 probably reflects the 
functional segmentation of the proximal tubule, with endocytosis being particularly active in 
the S1-S2 segments whereas secretory pathways take place in the S3 segment.180  
 Our cross-sectional study has to be interpreted in the context of the study setting. We 
report independent association between biomarkers and outcome of a relatively high number 
of young ADPKD patients. We are not able to conclude about causal relationships between 
urinary biomarkers and outcome parameter. The parameters were only investigated at a single 
time point and we are not able to infer whether or not biomarker excretion precedes decrease 
in renal function and increase in kidney volume. Furthermore, our results are based on a 
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single centre in the absence of comparative groups of healthy volunteers or other CKD 
patients, making it impossible to assess the specificity of our findings for ADPKD. To 
partially account for the study limitations, we performed internal validation of our data set by 
bootstrapping. Despite adjustment for multiple confounders of our predictive models, we are 
not able to fully eliminate the potential for bias and confounding. We followed a robust and 
reliable statistical approach to investigate the diagnostic properties of different urinary 
biomarkers in a large cohort of ADPKD patients in early disease stage. Based on our results 
we hypothesize that osmolality, UACR and KIM-1 may have the property to assess disease 
state at early ADPKD disease course, whereas NGAL, UMOD and CC16 seem not to qualify 
as biomarkers. Further studies are necessary to define the biomarker properties of the 
investigated parameter to predict disease burden in ADPKD. 
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Abstract 
Background: Macrohematuria is common in Autosomal Dominant Polycystic Kidney 
Disease (ADPKD) and associated with renal volume as well as hypertension.  In contrast, 
microhematuria is rarely investigated and commonly asymptomatic in ADPKD. In our study 
we investigate the prevalence and incidence of microhematuria, the determinants of 
microhematuria and potential association of microhematuria with outcomes of ADPKD. 
Methods: 171 ADPKD patients with preserved kidney function underwent MRI assessment 
and physical examination at each study visit. Dipstick analysis and subsequent urine 
microscopy were performed to assess microhematuria in spot urine samples. Correlation and 
regression analyses were performed to identify disease indices that are associated with 
microhematuria in ADPKD. 
Results: 171 ADPKD patients (31.8 ± 8.3 years, 59.1% male) with a mean eGFR of 92.6 ± 
19.3 ml/min/1.73m2, were followed over a median of 320 days. At study visits, a total of 50 
events of microhematuria were recorded. Patients with microhematuria at baseline had lower 
eGFR, higher systolic blood pressure and higher values of proteinuria and albuminuria 
compared with patients without microhematuria at baseline. Microhematuria was, beside 
others, significantly negatively correlated with eGFR and positively correlated with 
macrohematuria and number of macrohematuric episodes. eGFR, systolic blood pressure and 
24-hour albuminuria were significantly associated with microhematuria. 
Conclusion: The prevalence and incidence of microhematuria in our cohort was low. 
Microhematuria was correlated with kidney function, systolic blood pressure, macrohematuria 
as well as albuminuria and proteinuria in our cohort of ADPKD patients. Importantly, 
increasing TKV, serum creatinine, protein-creatinine ratio as well as decreasing eGFR are 
predictive for microhematuria. 
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Introduction 
 Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent 
hereditary kidney disease, affecting approximately one in thousand life births.66 The 
continuous development and progression of bilateral renal cysts destroys functional kidney 
parenchyma and leads to massive enlargement of the kidneys. Kidney function is stable over 
decades and starts to decline when cysts replace the majority of renal tissue, ultimately 
leading to kidney failure in 50% of the patients between their 50 and 60s years of life. Since 
ADPKD is a systemic disease, the clinical presentation is manifold. The increased mortality in 
ADPKD is attributed to cardiac abnormalities and intracranial aneurysm beside others. Early 
clinical symptoms include hypertension, microhematuria and flank pain.66 In contrast, 
nephrolithiasis, cyst hemorrhage and macrohematuria are more pronounced in advanced state 
and correlate with kidney size.20,70,71 Urine sediment abnormalities like hematuria are a risk 
factor for an accelerated disease progression in ADPKD.13,69,73-76 Macrohematuria, the visible 
presence of blood in urine, occurs in 30 to 50% of ADPKD patients.69,70 In ADPKD, episodes 
of macrohematuria are associated with increased renal volume and hypertension. Early and 
recurrent episodes are associated with more severe disease course and worse renal 
survival.9,71,77 Causes for macrohematuria in ADPKD are the rupture of cyst lining vessels due 
to overactive vascular endothelial growth factor resulting in enhanced angiogenesis in the 
kidney.71,10 Furthermore nephrolithiasis and urinary tract infections may explain lower and 
upper urinary tract hematuria.71 Under physiological conditions erythrocytes are present only 
to a small extent in human urine. However, the presence of heme in the tubular system is per 
se a risk factor and may exert cytotoxicity and promote kidney function deterioration.181 
Macrohematuria is usually short lived but tends to be recurrent in ADPKD. Macrohematuric 
durations exceeding one week need to be screened for neoplasm.71,182 Microscopic hematuria 
in ADPKD is of non-glomerular origin, remains often undetected,  and rarely reported. The 
course is often asymptomatic.78 Up to 60% of ADPKD patients undergo at least one episode 
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of micro- or macrohematuria.77,13 The aim of the study was to characterize ADPKD patients in 
terms of microhematuria and to identify the role of microhematuria with the outcome of 
ADPKD patients. 
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Methods 
Study subjects 
 Subjects included in this study belong to the well-described SUISSE ADPKD cohort, 
an ongoing observational longitudinal study conducted at the University Hospital of Zurich, 
Switzerland. 14,50 Since March 2006, patients diagnosed with ADPKD according to Ravine 
criteria, aged 18 to 40 years and with an eGFR of minimum 70 ml per min per 1.73m2 
(according to CKD-EPI formula) qualified for inclusion.5 Patients were gradually enrolled in 
the study. The study was conducted according to the Declaration of Helsinki and Good 
Clinical Practice Guidelines. The local ethical board approved the study and all patients 
provided written informed consent.  
 
Study procedure 
 Study subjects were invited to the outpatient clinic at the Division of Nephrology 
(University Hospital Zurich). At study visit the medical history was obtained, including 
medication and complications related to ADPKD. A brief physical examination including 
blood pressure measurement was performed. Blood pressure was measured using an 
oscillometric blood pressure device (Boso-Medicus, Jungingen, Germany) in duplicate at each 
arm after 5 minutes of rest in sitting position. Hypertension was defined as systolic blood 
pressure above 140 mmHg and/or diastolic blood pressure above 90 mmHg or 
antihypertensive treatment. Fresh morning midstream spot urine and blood samples were 
collected at study visit. Prior to the study visit all patients collected 24-hour urine.  
 
Laboratory measurements 
 Serum creatinine and urinary creatinine were analyzed using the modified Jaffé 
method traceable to an isotope-dilution mass spectroscopy reference. Renal function was 
assessed using the CKD-EPI formula and CKD stages were defined according to KDIGO 
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2012 CKD Guideline for CKD stage 1 to 4.16 Urinary protein was assessed using 
turbidimetry. Urinary albumin was analyzed with immunoturbidimetry. The analysis of urine 
osmolality was performed by cryoscopy. 
 
MRI and kidney volumetry 
 Patients underwent Magnetic Resonance Imaging in the absence of contrast media 
according to a standardized protocol. Two independent trained observers in a blinded fashion 
assessed kidney volume in stereological manner. Variability was calculated as concordance 
correlation coefficients (95% CI) and were 1.000 (0.999–1.000) for intraobserver and 0.996 
(0.995 – 0.999) for interobserver correlations.14 Total kidney volumes (TKV) were calculated 
by adding the volume of right and left kidney.  
 
Urinalysis 
 Fresh morning midstream spot urine samples were processed according to European 
Urinalysis Guidelines.183 The dipstick method (Combur 10 dipsticks, Roche Diagnostics, 
Mannheim, Germany) was applied to analyze all spot urine samples. Miditron Junior II 
(Roche Diagnostics, Mannheim, Germany), a semi-automated reflectance photometer was 
used to analyze the presence of erythrocytes, despite other parameters. The reference range 
for erythrocytes is 0 to 5 erythorcytes per µl (Ery/µl) with a practical detection limit of 5 
Ery/µl or 0.03 mg/dl Hb (corresponds to 10 Ery/µl) according to the manufacturers protocol. 
A positive dipstick analysis required subsequent microscopic examination. 10 ml of urine 
samples positive for erythrocytes were centrifuged for 5 minutes at 1,500 revolutions per 
minute (rpm). Urine sediment was obtained by removing the supernatant and analyzed by a 
trained observer using a phase contrast microscope (Leica Microsystems, Wetzlar, Germany) 
at a magnification of x400 to measure erythrocytes, leukocytes, epithelial cells, crystals, casts, 
bacteria and yeast in number per high power field (HPF). Results derived from 10 evenly 
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distributed HPFs. Results ≥ 5 erythrocytes per HPF were classified positive for 
microhematuria, according to in-house standards. A sediment sample with a positive result 
was considered as one event of microhematuria.  
 
Abbreviations: eGFR – estimated glomerular filtration rate, MRI – magnetic resonance imaging, TKV – total kidney volume, 
          RBC/HPF – red blood cells per high power field, MH – Microhematuria  
Figure 1: Flowchart of study process  
 
Statistical Analysis 
 SPSS 21 and SAS 9.4 were used for data analysis and preparation of figures. The 
study population was characterized by using univariate methods. Results are given as means 
(± standard deviation) and median (interquartile range). Point-biserial correlation was applied 
to investigate correlation of various disease indices with microhematuria at baseline. 
Contingency tables were established to analyze the correlation of dichotomous variables. T-
test for normal distributed parameter and Mann-Whitney-U-Test for not normal distributed 
variables have been applied to investigate differences in the stratified study population at 
baseline. Uni- and multivariate logistic regression analyses were used to investigate 
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determinants of microhematuria and the potential association with outcomes of ADPKD at 
baseline and at follow up. Univariate and multivariate logistic mixed effects models for 
correlated repeated measures data were done with the software package SAS 9.4. (SAS 
Institute Inc., Cary, NC) on a 64-bit workstation. The GLIMMIX procedure was used with 
maximum likelihood estimation with an adaptive Gauss-Hermite quadrature. Simplified 
models were selected over more complex models using the Akaike Information Criterion 
(AIC). P-values of <0.05 were considered significant. 
 
Results 
Demographics 
 A total number of 171 patients were included in the study. Data were collected from 
626 visits. The mean age of the study population was 31.8 ± 8.3 years and 40.9% of the 
patients were female. The mean BMI of the study population at baseline was 24.3 ± 5.1 
kg/m2. With a mean eGFR of 92.6 ± 19.3 ml/min/1.73m2, the majority of the patients 
belonged to CKD stage 1 (eGFR ≥ 90 ml/min/1.73m2) and 2 (eGFR = 60 – 89 
ml/min/1.73m2). 63.7% were classified as hypertensive, whereas 40.9% of the study 
population received antihypertensive treatment. The mean systolic and diastolic blood 
pressure was 135 ± 15 mmHg and 85 ± 10 mmHg, respectively. The median total kidney 
volume of the entire study population was 851.7 cm3 (IQR, 544.4 – 1244.7). The 24-hour 
urine collection revealed a mean creatinine value of 7.12 ± 3.43 mmol/l. The mean urine 
osmolality in 24-hour urine collection was 446.0 (± 174.6) mosmol/kg H2O. The median 
albumin-creatinine ratio was 9.20 mg/mmol (IQR, 5.40 – 22.05) in spot urine samples. Urine 
sediment analysis revealed calcium oxalate crystals in one patient and urate crystals in two 
patients at baseline visit. Questionnaires about ADPKD related symptoms and comorbidities 
showed that 23.9% of the study population experienced at least one event of macrohematuria 
during the course of ADPKD until baseline visit. Overall, these 26 patients reported 109 
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episodes of macrohematuria, with a maximum of 45 events per patient. Cyst infections have 
been reported by 25 (14.6%) patients and 62 (36.3%) experienced flank pain before baseline 
visit.  
 The study population was stratified according to the presence and non-presence of 
microhematuria at baseline visit, and into a group of patients without baseline microhematuria 
but with microhematuria during follow up. Patients without microhematuria were 
significantly different compared with patients with microhematuria at baseline in terms of 
serum creatinine and eGFR. Renal function, assessed as eGFR was significantly lower in 
patients with microhematuria compared with patients without microheamturia at baseline 
(81.6 ± 17.9 ml/min/1.73m2 versus 93.6 ± 19.1 ml/min/1.73m2). Furthermore, systolic blood 
pressure (145 ± 18 versus 134 ± 15 mmHg), 24-hour proteinuria (0.1063 ± 0.0753 versus 
0.0661 ± 0.0355 g/l) and 24-hour albuminuria (34.85 (IQR, 10.78 – 101.15) versus 9.80 (IQR, 
5.90 – 22.83) mg/l) were higher in patients with microhematuria compared with patients not 
presenting microhematuria at baseline visit. Patients that were positive for microhematuria 
during the follow-up are only significantly different for TKV (1137.4 (IQR, 868.6 – 1643.5) 
versus 791.1 (IQR, 520.1 – 1203.3) cm3) compared to patients without microhematuria at 
baseline (Table 1). 
 The supplementary tables S1 and S2 show the stratification of the study population 
according to CKD stages and to TKV below and above median.  
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Table 1: Characteristics of patients with and without microhematuria at Baseline Visit and at Follow up  
Characteristic Total 
 
N = 171 
Patients without 
microhematuria at BL 
N = 157 
Patients with 
microhematuria at BL 
N =14 
Patients with 
microhematuria at Follow 
up (but not at BL) 
N = 16 
Age – years 31.8 ± 8.3 31.5 ± 8.3 34.8 ± 8.1 32.9 ± 6.2 
Sex – no. (%)     
Female 70 (40.9) 67 (42.7) 3 (21.4) 5 (31.2) 
Male 101 (59.1) 90 (57.3) 11 (78.6) 11 (68.8) 
Weight – kg 76.5 ± 16.4 76.4 ± 16.5 77.9 ± 15.5 79.6 ± 24.9 
BMI – kg/m2 24.3 ± 5.1 24.2 ± 5.2 24.9 ± 4.3 25.1 ± 4.9 
Serum creatinine – (µmol/l) 88.3 ± 20.2 87.1 ± 19.3 102 ± 25.9* 96.8 ± 28.6 
eGFR – ml/min/1.73m2 92.6 ± 19.3 93.6 ± 19.1 81.6 ± 17.9* 86.2 ± 17.9 
CKD stage – no. (%)     
Stage 1 89 (52.0) 84 (53.5) 4 (28.6) 5 (31.2) 
Stage 2 75 (43.9) 66 (42.0) 9 (64.3) 10 (62.5) 
Stage 3 7 (4.1) 7 (4.6) 1 (7.1) 1 (6.3) 
Blood pressure – mmHg     
Systolic 135 ± 15 134 ± 15 145 ± 18* 137 ± 15 
Diastolic 85 ± 10 85 ± 10 88 ± 12 87 ± 9 
Hypertension – no. (%) 109 (63.7) 97 (61.8) 12 (85.7) 11 (68.8) 
Antihypertensive medication – no. of prescriptions 
(%) 
70 (40.9) 59 (37.6) 11 (78.6) 5 (31.3) 
ACE 66 56  10  4 
Diuretics 22 17  5 1 
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others (BB, CCB, SIRA) 18 14  4 4 
TKV – cm3 851.7  
(IQR, 544.4 – 1244.7) 
791.1  
(IQR, 520.1 – 1203.3) 
1202.6 
(IQR, 796.2 – 1202.6) 
1137,4* 
(IQR, 868,6 – 1643,5) 
24h Urine     
Creatinine – mmol/l 7.12 ± 3.43 7.12 ± 3.49 7.09 ± 2.48 7.56 ± 2.64 
Protein – g/24h 0.142 ± 0.091 0.131 ± 0.070 0.253 ± 0.189* 0.120 ± 0.036 
Albumin – mg/24h 22.45  
(IQR, 13.20 – 54.05) 
20.90  
(IQR, 12.98 – 46.90) 
83.25* 
(IQR, 23.53 – 158.25) 
43.60  
(IQR, 19.93 – 67.48) 
Osmolality – mosmol/kg H2O 446.0 ±174.6 446.5 ± 178.7 439.5 ± 116.6 467.6 ± 156.9 
Spot urine     
Creatinine – mmol/l 11.56 ± 6.34 11.47 ± 6.34 12.53 ± 6.45 10.39 ± 5.82 
Protein/Crea – g/mmol 0.009  
(IQR, 0.006 – 0.012) 
0.008  
(IQR, 0.006 – 0.011) 
0.016 
(IQR, 0.007 – 0.021) 
0.008  
(IQR, 0.006 – 0.115) 
Albumin/Crea – mg/mmol 2.000  
(IQR, 0.900 – 4.200) 
1.800  
(IQR, 0.900 – 3.600) 
6.850 
(IQR, 2.425 – 12.250) 
2.600  
(IQR, 1.700 – 3.950) 
Osmolality – mosmol/kg H2O 562.78 ±204.77 561.48 ± 207.49 576.71 ± 178.71 511.9 ± 192.6 
Urine sediment     
Calcium oxalate crystals –no. of patients 1 1 0 1 
Urate crystals – no. of patients 2 0 2 0 
Macrohematuria     
Present before/at BL – no.  26 (23.9) 20 (18.3) 6 (42.9) 5 (31.3) 
Age at first event – years 26.3 ± 6.1 26.6 ± 6.2 25.1 ± 6.2 24.6 ± 7.2  
Episodes until BL – no. 109 34 75 12 
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Cyst infection (present before/at BL) – no. of 
patients 
25 (14.6) 20 (12.7) 5 (35.7) 5 (31.3) 
Flank pain (present at or before/at BL) – no. of 
patients 
62 (36.3) 53 (33.8) 9 (64.3) 8 (50.0) 
Abbreviations: eGFR – estimated glomerular filtration rate. TKV – total kidney volume, ACE – angiotensin converting enzyme, BB=beta blocker, CCB=calcium channel blockers, BL – baseline visit. 
Values are means ± standard deviation and numbers (percentage), TKV, 24-hour albumin, protein-creatinine ratio, albumin-creatinine ratio are reported as median (interquartile range). *p<0.05 
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Prevalence and incidence of hematuria  
 Over the complete study duration, 50 events of microhematuria were recorded in 30 
patients. The prevalence at baseline was 8.2% with 14 microhematuria events at baseline visit 
in 171 patients. The incidence rate for an episode of microhematuria was 29.2% in our cohort. 
The total study duration covered 108,675 patient days. The median follow up time was 320 
days with a median visit interval of 190 days. 16 patients were positive for microhematuria 
during follow up without presenting microhematuria at baseline. Over the study duration, 7 
patients experienced more than one event of microhematuria. The maximum number of 
events was 5, which was recorded in 2 patients. In total, 233 positive dipstick tests were 
detected over the study duration. Thereof, 50 (21.5%) were confirmed by microscopic 
evaluation of erythrocytes per HPF (Table 2). Due to the nature of the study with consecutive 
enrollment of patients, no patient was considered as lost of follow up during observation 
period.  
 
Table 2: Positive dipstick vs. positive microscopic examination 
visit No of 
patients 
Positive 
dipstick 
 
– no. (%) 
Positive 
microscopic 
examination  
– no. (%) 
Positive microscopic 
examination in relation 
to positive dipstick  
– % 
Correlation between 
dipstick and 
microscopic 
examination 
1 171 58 (33.9) 14 (8.2) 24.1  
 
 
 
 
 
 
 
 
r2 = 0.383, p<0.05 
2 149 55 (36.9) 9 (6.0) 16.4 
3 36 11 (30.6) 2 (5.6) 18.2 
4 52 26 (50.0) 6 (11.5) 23.1 
5 69 29 (42.0) 4 (5.8) 13.8 
6 52 22 (42.3) 5 (9.6) 22.7 
7 41 11(26.8) 4 (9.8) 36.4 
8 44 16 (36.4) 5 (11.4) 31.3 
9 12 5 (41.7) 1 (8.3) 20.0 
Σ   233 50 21.5 
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Correlation of microhematuria with disease indices of ADPKD at baseline 
 Point-biserial correlation and contingency tables were used to assess correlation of 
microhematuria with disease indices of ADPKD at baseline (Table 3, Figure 2). Thereof the 
number of episodes of macrohematuria showed highest correlation coefficient (r2 = 0.488, p = 
0.011) compared with other parameter. Furthermore renal function (eGFR) was significantly 
negatively correlated to microhematuria at baseline (r2 = - 0.171, p = 0.025). Systolic blood 
pressure was significantly correlated with microhematuria (r2 = 0.183, p = 0.016), whereas 
diastolic blood pressure was not. A positive correlation of 24-hour albuminuria (r2 = 0.337, p 
= 0.010), and 24-hour proteinuria (r2 = 0.245, p = 0.002) was found. The albumin-creatinine 
ratio from spot urine was also significantly correlated with microhematuria (r2 = 0.213, p = 
0.007). The establishment for contingency tables and appropriate bar graphs (Figure 3), 
depicting the correlation between two dichotomous parameters, manifested a positive 
correlation of high significance between macrohematuria and microhematuria (r2 = 0.193, p = 
0.0045). 
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Table 3: Correlation of disease indices with microhematuria at baseline 
 age eGFR CKD 
stage 
TKV Hyper-
tension 
Bp  
sys 
Bp 
dia 
Macro- 
hematuria 
Episodes of 
Macro-
hematuria  
24h 
Albuminuria 
24h 
Proteinuria 
Spot urine  
Alb/Crea 
Spot urine  
Prot/Crea 
Flank 
pain 
Cyst 
infection 
r2 0.109 - 0.171 0.138 0.147 0.136 0.183 0.090 0.193 0.488 0.337 0.245 0.213 0,124 0.092 0.136 
p 0.156 0.025 0.073 0.055 0.075 0.016 0.240 0.045 0.011 0.010 0.002 0.007 0.132 0.343 0.159 
Abbreviations: eGFR—estimated glomerular filtration rate, TKV—total kidney volume, Bp sys—systolic blood pressure, Bp dia—diastolic blood pressure, Alb/Crea—albumin-creatinine-ratio, 
Prot/Crea—protein-creatinine-ratio. 
 
 
 
 
 
 
 
 
 
 
 
 
 
First Author Manuscripts – 93 #
#
   
   
First Author Manuscripts – 94 #
#
   
 
 
Figure 2: Correlation of microhematuria with disease indices of ADPKD 
First Author Manuscripts – 95 #
#
 
 
Figure 3: Bar graphs of binary disease indices in ADPKD 
First Author Manuscripts – 96 #
#
Uni- and multivariate Regression Analysis of parameters associated with 
microhematuria at baseline and follow up 
 Univariate and subsequent multivariate regression analysis was performed to identify 
the effect of various parameters on the occurrence of microhematuria. In the univariate 
analysis the continuous variables age, TKV, eGFR, blood pressure, 24h-albuminuria and the 
number of macrohematuric episodes were included as well as the dichotomous variable sex. 
Table 4 shows the results for univariate logistic regression with the regression factor B and 
the appropriate odds ratio. Renal function, expressed as eGFR (B = -0.034, p = 0.030), 
systolic blood pressure (B = 0.041, p = 0.020) and urinary 24-hour albumin excretion (B = 
0.028, p = 0.001) show statistical significance in the univariate logistic regression. An 
increase in eGFR is associated with a decreasing risk to get microhematuria of about 3.3% 
(OR = 0.967) in our cohort. When systolic blood pressure increases by about 1 mmHg, the 
risk for microhematuria will increase by 4.2% (OR = 1.042). With each increase in 24-hour 
albuminuria, the risk for microhematuria will increase by 2.8% (OR = 1.028). Age, sex, TKV, 
diastolic blood pressure and macroscopic episodes are not significantly increasing the risk for 
experiencing an event of microhematuria in our cohort.  
 
Table 4: Univariate logistic regression of various disease indices with microhematuria at  
               baseline 
Variable Regression coefficient 
B 
p   Odds ratio (CI 
95%) 
Age – age  0.045  0.158 1.046 (0.982 – 1.114) 
Sex (male)  1.004  0.135 2.730 (0.733 – 10.169) 
eGFR – ml/min/1.73m2 - 0.034  0.030 0.967 (0.938 – 0.997) 
TKV – cm3  0.001  0.068 1.001 (1.000 – 1.001) 
BP systolic – mmHg  0.041 0.020 1.042 (1.006 – 1.078) 
BP diastolic – mmHg  0.032  0.241 1.033 (0.979 – 1.089) 
Episodes of macrohematuria – no.  0.177  0.207 1.194 (0.907 – 1.572) 
24-hour albuminuria – mg/24h 0.016 0.001 1.017 (1.007 – 1.027) 
Spot urine Alb/Crea – mg/mmol 0.383 0.075 1.467 ( 0.963 – 2.237) 
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Subsequently multivariate logistic regression was performed (Table 5). In association model 
1, including age, sex and TKV, age showed a significant influence to experience 
microhematuria (B = 0.034, p = 0.036), when adjusted for male and TKV. Interestingly, total 
kidney volume seems not to have any influence on the occurrence of microhematuria in 
univariate and multivariate analysis. In association 2, systolic blood pressure (B = 0.063, p = 
0.013), remains significant following adjustment for eGFR, TKV and diastolic blood 
pressure. No significance was found in association 3, containing TKV, systolic and diastolic 
blood pressure, episodes of macrohematuria as well as 24h-albuminuria.  
 
Table 5: Multivariate logistic regression of various disease indices with microhematuria at baseline 
Variable Association 1 Association 2 Association 3 
 Regression 
coefficient 
B 
p Regression 
coefficient  
B 
p Regression 
coefficient  
B 
p 
Age – years 0.034 0.036     
Sex (male) 0.853 0.070     
eGFR – ml/min/1.73m2   - 0.032 0.076 - 1.385 0.998 
TKV – cm3 0.000 0.000  0.000 0.039   
BP systolic – mmHg    0.063 0.013   0.261 0.999 
BP diastolic  – mmHg    -0.050 0.209 - 4.534 0.996 
Episodes of Macrohematuria – no.       5.556 0.996 
Spot urine Alb/Crea – mg/mmol       7.402 0.996 
 
 Univariate logistic mixed effects models were established to evaluate the impact of 
disease indices on the outcome parameter microhematuria (Table 6). Longitudinally, eGFR is 
significantly inversly associated with microhematuria. An eGFR that is 5ml/min/1.73m2 
higher than the mean was associated with a decreased risk of microhematuria (OR = 0.792 
(0.694 – 0.904), p = 0.0006). An increase in serum creatinine per 10 µmol/l was also 
associated with a higher risk for microhematuria (1.440 (1.181 – 1.756), p = 0.0003). The risk 
of microhematuria is increasing with spot urine albumin creatinine-ratio per 0.1 mg/mmol 
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increase (OR = 1.006 (1.001 – 1.010) p = 0.0089). Per each increase of kidney volume of 100 
cm3, the risk for experiencing microhematuria increased (1.088 (1.016 – 1.166), p = 0.0154). 
 
Table 6: Longitudinal univariate logistic regression of various disease indices with microhematuria 
Variable Difference for 
odds ratio 
Odds ratio (CI 95%) p 
Weight  10 kg 0.990 (0.847 – 1.658) 0.3214  
Duration from baseline  365 days 1.044 (0.751 – 1.450) 0.9804  
eGFR  5 ml/min/1.73m2 0.792 (0.694 – 0.904) 0.0006  
TKV  100 cm3 1.088 (1.016 – 1.166) 0.0154  
BP systolic 10 mmHg 1.222 (0.907 – 1.646) 0.1869 
BP diastolic 10 mmHg 1.486 (0.946 –2.336) 0.0858 
Serum creatinine  10 µmol/l 1.440 (1.181 – 1.756) 0.0003  
Spot urine Alb/Crea 0.1 mg/mmol 1.006 (1.001 – 1.010) 0.0089 
 
 Subsequently, binary disease parameters were assessed for their association with 
microhematuria (Table 7). Thereof, flank pain (OR = 0.368 (0.186 – 0.730), p = 0.0043) and 
macrohematuria (OR = 0.299 (0.126 – 0.708), p = 0.0043) were significantly associated with 
microhematuria. Anorganic crystals, like calcium oxalate and urate crystals in patients’ urine 
and cyst infection were not significantly associated with microhematuria.  
 
Table 7: Longitudinal univariate logistic regression of binary disease indices with microhematuria 
Variable Difference for odds ratio Odds Ratio (95%CI) p 
Urinary crystals No urine crystals vs. urine crystals 0.184 (0.025 – 1.381) 0.0996  
Cyst infection  No cyst infection vs. cysts infection  1.346 (0.290 – 8.657) 0.7542  
Flank pain  No flank pain vs. flank pain 0.331 (0.148 – 0.738) 0.0070  
Macrohematuria No macrohematuria vs. macrohematuria 0.308 (0.108 – 0.880) 0.0280 
 
The multivariate logistic regression based on longitudinal data, revealed that microhematuria 
is independently related to eGFR (p = 0.0035) and spot urine albumin to creatinine ratio (p = 
0.0352) (Table 8). The addition of neither serum creatinine nor total kidney volume did 
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significantly improve the combined model given the strong correlation of serum creatinine 
and total kidney volume with eGFR (Table 9). 
 
Table 8: Longitudinal multivariate logistic regression of eGFR and spot urine Alb/Crea with 
microhematuria 
Variable p AIC 
eGFR 0.0035  277.92  
  Spot urine Alb/Crea 0.0352  
 
Table 9: Longitudinal multivariate logistic regression of eGFR, TKV and spot urine Alb/Crea with 
microhematuria 
Variable p AIC 
eGFR 0.0319  275.19  
TKV  0.5216  
Spot urine Alb/Crea 0.0318  
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Discussion 
 Hematuria is a risk factor for disease progression in ADPKD. Whereas 
macrohematuria is known to occur in approximately 50% of patients and is associated with 
increased renal volume, only limited data is available on microhematuria in ADPKD. The 
data available indicates that microhematuria is associated with worse renal outcome, 
measured as increase in serum creatinine.70  
 In our study we investigated microhematuria in a cohort of young ADPKD patients 
with a mean eGFR of 92.6 ± 19.3 ml/min/1.73m2. The effect of various parameters on the 
occurrence of microhematuria were investigated. In general, microhematuria may originate 
from any site of the urinary tract and may per se be a sign of an underlying disease. It is often 
detected accidently by urinary analysis. Regular screening is not performed routinely and 
microhematuria may occur without patients notice. Furthermore minor amounts of 
erythrocytes may be also excreted in healthy subjects. To prevent misclassification we 
performed a robust laboratory approach. A sediment analysis following each positive dipstick 
test was performed to distinguish between microhematuria and other reasons for erythrocytes 
in urine, like menstruation or urinary tract infections. False positive dipstick results were 
excluded from statistical analysis. We classified 5 or more erythrocytes per HPF as one event 
of microhematuria. However, different thresholds exist in the literature, ranging from 3 to 5 
erythrocytes per HPF, challenging the comparison of results with other studies. We classified 
microhematuria as a dichotomous variable, with possible manifestation: yes or no. 
 The prevalence of microhematuria in the general population, as shown in population 
based studies, ranges from 0.19 to 16.1%.79 Studies in older healthy males revealed a 
prevalence up to 21%, indicating a strong age dependency.184 Our study population was 
followed over 108,675 patient days with a median follow up of 320 days. The prevalence of 
microhematuria at baseline of 8.1% might appear low. However, taken into account the 
characteristics of our population: patients are rather young and in general at an early stage of 
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their disease, with the majority of patients belonging to CKD stage 1 and 2. Nevertheless, 
even in this young study cohort we found significant differences after stratification in 
subgroups according to the appearance of microhematuria. Principally, due to the unnoticed 
appearance of microhematuria during disease course, investigators may probably miss events. 
Overall, we recorded 50 events of microhematuria. Compared to other studies indicating that 
up to 50% of ADPKD patients experience hematuria, often in recurrent episodes, the majority 
in our cohort experienced microhematuria at a single time point over the study duration. 
Seven patients exhibited 2 to a maximum of 5 events during the observation period. Only a 
small fraction of subjects belonged to CKD stage 3 at baseline (7 patients, 4,1%), as the most 
advanced stage in the present study at baseline visit.  
 In our cohort, microhematuria was significantly inversely correlated with eGFR. eGFR 
was also associated with microhematuria in baseline and longitudinal regression analysis. A 
decrease in renal function is significantly increased the risk of experiencing microhematuria 
in our cohort of young ADPKD patients. Therefore, we may conclude that beside 
macrohematuria also microhematuria as a potential risk marker for disease progression in 
addition to other well established risk factors.  
 Microhematuria was also correlated with macrohematuria and the number of 
macrohematuric events in our cohort. Also, the longitudinal regression analysis revealed an 
augmented risk for microhematuria. Based on these results it seems that macrohematuria may 
follow microhematura in a timely manner. However, patients without microhematuria at 
baseline reported 109 episodes of macrohematuria before baseline visit. Macrohematuria, due 
to cyst rupture or other events, may have detrimental effects on the kidney due to release of 
free iron and the occurrence of reactive oxygen species. Studies have shown that in patients 
the presence and number of events of macrohematuria are associated with hypertension and 
higher kidney volume.34,70,79 In our study, systolic blood pressure was significantly correlated 
and associated with microhematuria at baseline. No association could be established in the 
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longitudinal analysis. Hypertension is a common and early sign of ADPKD in up to 80% of 
the patients with a mean age of 31 years.10,34 The prevalence of hypertion in our cohort was 
63.7%.  
 We found also a significant correlation between microhematuria and urinary 
parameters, like 24h-albumin excretion and albumin-creatinine and protein-creatinine ratio in 
spot urine. Under normal physiological conditions only 1 %, approximately 30 mg, of the 
filtered albumin is excreted per day.85 Even the median of the complete cohort was in a 
normal range; 24-hour albuminuria was significantly higher in patients with microhematuria 
compared with patients without microhematuria. Patients with microhematuria at baseline 
visit can be classified as microalbuminuric, with a median albumin excretion above 45 mg per 
24 hours. 
To date, total kidney volume is a preferred parameter to accurately assess disease progression 
in ADPKD patients compared with eGFR. In our study, total kidney volume was not 
significantly correlated with microheamturia but was associated in longitudinal regression 
analysis. Each increase in kidney volume of about 100 cm3 increased the risk of experiencing 
microhematuria by about 6.6%.  
 No data were available on the erythrocyte morphology to distinguish between 
glomerular or tubular occurrence of erythrocytes. Since macrohematuria is of glomerular 
origin in ADPKD, microhematuria is classified as tubular origin in the literature.71,11,12 Since 
nephrolithiasis and urinary tract infections may explain lower and upper urinary tract 
hematuria in ADPKD, further studies are required to evaluate the exact cause of 
microhematuria in ADPKD patients.71 
 In summary, our study shows, that microhematuria is associated with different disease 
indices in a longitudinal fashion. Renal function, measured as eGFR, TKV as well as 
albumin-creatinine ratio were associated with microhematuria. Flank pain and 
macrohematuria episodes were predictive for microhematuria. Patients positive for 
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microhematuria may have an accelerated disease course in terms of eGFR, serum creatinine, 
24-hour albuminuria and systolic blood pressure. If microhematuira would qualify as a 
marker to assess early disease state ADPKD has to be evaluated in further studies. 
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Supplement 
Table S1: Baseline characteristics of the study population according to CKD stage 
Characteristic CKD stage 1 
N = 89 
CKD stage 2 
N = 75 
CKD stage 3 
N = 7 
Age – years 28.1 ± 6.7 35.0 ± 8.0 37.5 ± 9.2 
Sex – no. (%) # # #
Female 39 (43.8) 29 (38.7) 2 (28.6) 
Male 50 (56.2) 46 (61.3) 5 (71.4) 
Weight – kg 73.3 ± 14.4 79.4 ± 17.7 87.3 ± 17.2 
BMI – kg per m2 23.4 ± 4.4 24.9 ± 5.6 27.5 ± 5.0 
Serum creatinine – µmol/l 76.6 ± 12.4 97.6 ± 14.0 138.7 ± 29.5 
eGFR – ml/min/1.73m2 107.7 ± 11.2 78.5 ± 8.5 52.7 ± 6.5 
Blood pressure – mmHg    
Systolic 134 ± 15 136 ± 15 131.8 ± 12 
Diastolic 83 ± 11 87 ± 10 85.8 ± 7.1 
Hypertension – no. (%) 49 (55.1) 53 (70.7) 7 (100) 
Antihypertensive treatment – 
no. (%) 
20 (22.5) 43 (57.3) 7 (100) 
ACE – no. of prescriptions 18  41  7 
Diuretics – no. of    
prescriptions 
4 15 3 
Others (BB, CCB) – no. of  
prescriptions 
3  11 4 
TKV – cm3 648.9  
(IQR, 468.9 – 944.9) 
1035.8  
(IQR, 649.5 – 
1533.8) 
1925.3  
(IQR, 1251.9 – 
2134.7) 
24h Urine    
Creatinine – mmol/l 7.23 ±3.67 7.03 ± 3.29 6.67 ± 1.12 
Protein – g/l 0.0669 ± 0.0400 0.0683 ± 0.0371 0.0979 ± 0.0718 
Protein – g/24h 0.129 ± 0.072 0.146 ± 0.076 0.262 ± 0.269 
Albumin – mg/l 8.90  
(IQR, 5.25 – 8.90) 
13.15  
(IQR, 7.53 – 28.33) 
32.70  
(IQR, 4.40 – 54.40) 
Albumin – mg/24h 18.40  
(IQR, 11.60 – 46.20) 
27.80  
(IQR, 16.25 – 64.25) 
42.30  
(IQR, 12.98 – 
178.88) 
Osmolality – mosmol/kg  
H2O 
458.9 ± 191.2 433.2 ± 160.0 422.1 ± 92.7 
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Spot urine    
Creatinine – mmol/l 11.41 ± 6.85 12.02 ±5.89 8.56 ± 2.85 
Protein/Crea – g/mmol 0.008  
(IQR, 0.006 – 0.0110 
0.009  
(IQR, 0.006 – 0.012) 
0.0180  
(IQR, 0.0060 – 
0.0353) 
Albumin/Crea – mg/mmol 1.70  
(IQR, 0.80 – 3.20) 
2.20  
(IQR, 1.00 – 4.85) 
8.20  
(IQR, 1.00 – 13.80) 
Osmolality – mosmol/kg  
H2O 
576 .0 ± 231.2 559.5 ± 170.3 418.9 ± 119.2 
Urine sediment    
Calciumoxalat crystals 0 1 0 
Urate crystals 0 2 0 
Microhematuria     
Present at BL visit – no. (%) 4 (4.5) 9 (12.0) 1 (14.3) 
Macrohematuria     
Present before/at BL – no of     
patients (%) 
9 (10.1) 14 (18.7) 3 (42.9) 
Age at first event – years 26.3 ± 6.2 26.9 ± 6.1 23.8 ± 7.8  
Episodes until BL – no. 10  69 26 
Cyst infections (present 
before/at BL) – no. of patients 
16  8 (10.7) 1 (14.3) 
Flank pain (present before/at 
BL) – no. of patients 
31  27 (36.0) 4 (57.1) 
Abbreviations: eGFR – estimated glomerular filtration rate. TKV – total kidney volume, ACE – angiotensin converting 
enzyme, BB – beta blocker, CCB – calcium channel blockers, BL – baseline. Values are means ± standard deviation and 
numbers (percentage), TKV, 24-hour albumin, protein-creatinine ratio, albumin-creatinine ratio are reported as median 
(interquartile range). 
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Table S2: Baseline characteristics of the study population according to TKV.  
 # TKV below median ( ≤ 851.7 cm3) 
N = 86 
TKV above median 
( > 851.7 cm3) 
N = 85 
Age – years 29.8 ± 8.3 33.8 ± 7.9 
Sex – no. (%)   
Female 47 (54.7) 23 (27.1) 
Male 39 (45.3) 62 (72.9) 
Weight – kg 71.4 ± 13.8 81.7 ± 17.2 
BMI – kg per m2 23.2 ± 4.8 25.4 ± 5.1 
Serum creatinine – µmol/l 78.9 ± 14.5 97.8 ± 20.9 
eGFR – ml/min/1.73m2 100.9 ± 16.6 84.2 ± 18.2 
CKD stage – no. (%)   
Stage 1 57 (66.3) 32 (37.3) 
Stage 2 29 (33.7) 46 (54.1) 
Stage 3  0 (0) 7 (8.2) 
Blood pressure – mmHg   
Systolic 132 ± 16 139 ± 14 
Diastolic 82 ± 9 89 ± 10 
Hypertension – no. (%) 39 (45.3) 70 (82.4) 
Antihypertensive treatment – 
no. (%) 
21 (24.4) 49 (57.6) 
ACE – no. of prescriptions 19 47  
Diuretics – no. of   
prescriptions 
6 19 
Others (BB, CCB) – no. of  
prescriptions 
3  15 
24h Urine   
Creatinine – mmol/l 6.90 ± 3.81 7.34 ± 2.98 
Protein – g/l 0.0626 ± 0.0367 0.0752 ± 0.0437 
Protein – g/24h 0.118 ± 0.059 0.164 ± 0.109 
Albumin – mg/l 8.00 (IQR, 5.10 – 16.30) 19.10 (IQR, 8.20 – 
19.10) 
Albumin – mg/24h 15.95 (IQR, 10.20 – 28.30) 34.05 (IQR, 17.45 – 
76.00) 
Osmolality – mosmol/kg H2O 446.3 ± 195.0 445.8 ± 152.2 
Spot urine   
Creatinine –mmol/l 12.40 ± 7.07 10.70 ± 5.42 
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Protein/Crea – g/mmol 0.008  
(IQR, 0.005 – 0.0100) 
0.010  
(IQR, 0.007 – 0.013) 
Albumin/Crea – mg/mmol 1.30 (IQR, 0.70 – 2.58) 2.90 (IQR, 1.50 – 5.50) 
Osmolality – mosmol/kg H2O 609.9 ± 225.3 515.1 ± 170.1 
Urine sediment   
Calcium oxalate crystals 1 0 
Urate crystals 0 2 
Microhematuria    
Present before/at BL – no. of  
patients (%) 
3 (3.5) 11 (12.9) 
Macrohematuria    
Present before/at BL – no. of  
Patients (%) 
8 (9.3) 18 (21.2) 
Age at first event – years 27.5 ± 6.7 25.8 ± 6.1 
Episodes until BL – no. 11 98 
Cyst infections (present 
before/at BL) – no. of patients 
13 (15.1) 12 (14.1) 
Flank pain (present at or 
before/at BL) – no. of patients 
20 (23.3) 42 (49.4) 
Abbreviations: eGFR – estimated glomerular filtration rate. TKV – total kidney volume, ACE – angiotensin converting 
enzyme, BB – beta blocker, CCB – calcium channel blockers, BL – baseline. Values are means ± standard deviation and 
numbers (percentage), TKV, 24-hour albumin, protein-creatinine ratio, albumin-creatinine ratio are reported as median 
(interquartile range)
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Discussion and Conclusion 
 ADPKD is the most common inherited renal disease, affecting around 12,000 people in 
Switzerland. Half of the patients will turn to ESRD during disease course and will require renal 
replacement therapy. The generation and growth of bilateral cysts in the kidney start early in life, 
commonly in the absence of clinical signs. In absence of an established family history, ADPKD 
remains often undiscovered until disease related complications, like hypertension, pain, 
hematuria, urinary tract infections and others occur.  
 Research over the recent years has brought more insight into pathogenic processes 
underlying ADPKD and new drug targets were discovered. Despite the progress made, different 
features of ADPKD remain unexplained. The causes for a strong variability of disease course 
within the same family and the causes for interfamilial variability of disease course remain 
elusive.  
 Cystogenesis is continuously replacing functional renal parenchyma. The remaining 
functional nephrons tend to hyperfiltrate and thereby compensate for lost nephrons, explaining 
the apparently stable kidney function over decades. The traditional marker for kidney function, 
serum creatinine, will only change when cysts replace the majority of functional parenchyma. 
Also the eGFR, calculated from serum creatinine levels, stays within normal ranges and is not 
appropriate to assess the exact disease state. However, the assessment of disease state in early 
course is important: first, to define possible interventions, which are supposed to slow down 
progression and second, to identify patients that would benefit most from upcoming medical 
treatments.  
 Until very recently, no medication was approved for treatment of ADPKD in Europe. The 
application of the selective vasopressin 2 receptor antagonist Tolvaptan is now approved for its 
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ADPKD application in Japan, Canada and Europe. Tolvaptan reduced the growth rate in ADPKD 
and treatment was associated with lower disease burden in respect to pain compared with placebo 
group. Side effects, like polyuria and nocturia lead to higher discontinuation rates in the 
Tolvaptan group.  
 Other substances, targeting predominantly kidney volume, showed promising results in 
basic studies but failed to affect disease course under clinical evaluation.48,50,51 The mTOR 
Inhibitors Sirolimus and Everolimus slowed cyst growth and preserved renal function in an 
animal model.46,47,49 The failure in showing effects in clinical studies may be caused by dose 
limiting side effects, less follow up time and/or heterogeneity of study population in terms of 
baseline renal function and volume.185 
 The effect of synthetic long acting somatostatin analogues has been found by chance 
during treatment of endocrine tumors, where it reduced liver growth and decelerated kidney 
volume growth.185,44 The results available so far are insufficient to finally evaluate the effect of 
somatostatin analogues on ADPKD progression. In summary, the treatment options for ADPKD 
are scarce and an unmet need exists to evaluate patients that will undergo treatment, once the 
options are available in clinics. Since early disease course and fast progressive patients will 
benefit most, reliable biomarkers have to be established to evaluate these patients. 
 
Does conventional CKD treatment affect ADPKD outcome? 
 Standard care focuses mainly on the treatment of co-morbidities. Conventional treatment 
for CKD includes blood pressure control, RAAS inhibition, and low protein diet. These regimens 
seem not to be effective on the overall progression of ADPKD, since the incidence of ESRD in 
ADPKD did not substantially change in Europe between 1991 and 2010.186 The incidence rates 
for patients starting RRT due to ADPKD in the US from 2001 to 2010 was 7.5 cases per million 
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per year. The age of ESRD onset was 55.7 ± 13.2 years in 2001 to 2002 and remained unchanged 
during the period of observation.187 Results of the Danish National Registry on Regular Dialysis 
and Transplantation revealed an increase in RRT incidence from 6.45 cases per million in 1990 to 
1995 and 7.59 million cases in 2002 to 2007. The mean age of onset of ESRD in Denmark 
increased by about 4.7 years to 60.6 years. The results of Orskov et al indicate an improved 
survival of patients before ESRD.188 
 A rigorous blood pressure control to 95 – 100/60 – 75 mmHg with ACE inhibitors may 
slow the growth in kidney volume compared with standard blood pressure targets (120 –130/70 – 
80 mmHg).17 The Kidney Disease: Improving Global Outcomes (KDIGO) Initiative is providing 
evidence based clinical guidelines for treatment of CKD patients since 1997 to improve the 
diagnosis and the treatment of chronic kidney disease. 
 The outstanding attribute of ADPKD compared with other types of chronic kidney disease 
is that the disease starts early in life. This can be seen as an advantage but also as a disadvantage. 
Discovered early, treatment for co-morbidities can take place and may delay renal function loss. 
Staying undiscovered, symptoms may only occur once renal parenchyma is destroyed and late 
treatment initiation will not improve outcome.  
 Overall, the management of co-morbidities in APDKD may delay the need of RRT but 
will not substantially change disease course nor halt disease progression, which is most important 
for patients displaying PKD1 mutation, since they turn 20 years earlier to ESRD compared with 
PKD2 mutation. 
 
The need of prospective cohort studies  
 The research of ADPKD, especially in Europe, has been fragmented over the past years 
with several local smaller cohorts. Studies investigating disease progression were predominantly 
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retrospective and/or focussed on patients with advanced disease state. In contrast to the USA, in 
Europa no specific funding for research has been dedicated to ADPKD. Large prospective 
ADPKD studies, like CRISP and HALT-PKD in the USA are lacking in Europe. Large studies in 
Europe like the German CKD are not specifically investigating ADPKD.151 Standardized 
common guidelines for the management of ADPKD patients are lacking. The EuroCYST 
initiative contributes to close this gap. The initiative will identify progression factors and 
biomarkers; assess disease stage specific mortality, morbidity and health costs. This knowledge 
should translate into new diagnostic and therapeutic modalities for patients with ADPKD. The 
inclusion of subjects in currently 10 countries will offer a cross section of the European ADPKD 
population that is followed in a standardized fashion. The large pan-European observational 
cohort will serve as a scaffold and platform enabling researchers to study the pathogenesis, 
progression factors, mortality, co-morbidity as well as health economic issues relevant to 
ADPKD as a major cause of kidney disease. The data set of the EuroCYST study has been 
carefully selected to comprise fields that, one the one hand have been investigated only 
novercally in the past, like socio-economic situation, QoL and noxa of ADPKD patients. On the 
other hand, it will be possible to harmonize our data with already existing databanks. 
 Primary outcomes of the study will be biomarkers of disease progression and the 
association thereof with the onset and severity of ADPKD related outcomes in a European cohort 
presenting an eGFR of minimum 30 ml per min per 1.73m2 at baseline. To prevent selection bias 
and to represent early and advanced disease states an eGFR stratification at inclusion of 40 to 
60% of enrolled subjects with eGFR above and under 60 ml per min per 1.73 m2. 
 Beside the investigation of biomarkers in specimens of ADPKD patients a broad field of 
secondary objectives will be investigated in the EuroCYST study. The impact of disease on 
patients health status has seldom been investigated and insights of the QoL is predominantly 
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available from advanced stages and ESRD patients.189,190 The HALT-PKD investigators 
hypothesized a diminished health related QoL (HRQoL) in advanced disease state, which is 
associated with TKV in CKD stage 1 to 4. In fact, ADPKD related symptoms were only weakly 
associated with HRQoL and HRQoL was not associated with TKV in this study.22 ADPKD 
affects families and probably generations thereof. The communication of ADPKD within families 
may be difficult for patients and could lead to delay of discovery of ADPKD in siblings and 
probably delay medical treatment and intervention. We therefore conducted a questionnaire about 
planning a family and family information which will gain valuable information of the 
communication culture within families and the attitude towards ADPKD testing in respect to 
systematic imaging, genetic testing and the rate of incidental finding. The frequence of collecting 
blood and urine samples for biobanking and MRI should be intensified to have the possibility to 
accurately follow disease course and to investigate potentially biomarkers and their characterstic 
in ADPKD over a broad range of disease course. To even more strengthen the study, EuroCYST 
will follow the patients longitudinally and the duration and patient enrolment should be extended 
beyond the actual period of 3 annual follow up visits to follow the patients over a long disease 
duration and to specify co-morbidity and ADPKD related complications over the whole range of 
disease course.  
 Even so, the patient number of 1,100 is unique for a study on ADPKD in Europe, the 
quantity of enrolled subjects should be increased, by elevating the number of patients per study 
centre and/or by involvement of additional study centres in Europe. This will also give a broader 
picture of the patient characterstics throughout Europe.  
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Is TKV a prognostic marker? 
 Total kidney volume functions as surrogate endpoint for clinical studies in ADPKD. It is 
now commonly used by scientists but so far not accepted as primary endpoint in interventional 
studies by authorities like the FDA. The retardation in kidney volume growth and/or a total 
reduction in kidney volume are desired endpoints. Hard endpoints, like ESRD or death, are not 
practicable in ADPKD studies investigating early disease state. As shown in figure 3, renal 
function stays stable over decades and is therefore not an appropriate marker to assess the 
efficacy of an intervention.  
 
 
Figure 3: Renal function and TKV during disease course in ADPKD36 
 
 MRI and CT are desirable techniques to visualize and measure renal volume in ADPKD, 
whereas MRI has to be given preference due to lower radiation exposure. Patients with larger 
kidney volume at any given time point tend to be faster progressors with more rapid volume 
increase and more frequent occurrence of co-morbidities.13 At the time-point new medical 
treatments will become available, the question has to be answered which patients to select for 
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treatment. Fast progressing patients in an early state of disease would probably benefit most from 
an interventional therapy. Therefore, it is crucial to accurately identify these patients. Volume 
visualizing in ADPKD is most accurate applying MR-technique, with detection of 2 mm small 
cysts.14 Detrimental is its high technical demand, the cost and time intensity. Trained personnel 
has to perform the imaging in a standardized fashion applying defined settings, like sequences 
and slice thickness. Volume quantification is performed with stereological or midslice 
approaches with special programmes. Still, MR techniques are not clinical routine in all European 
countries. Irazabal et al developed a model to select patients for clinical studies based on kidney 
growth rate. Annual growth rates, starting from a theoretical baseline height adjusted renal 
volume of 150 ml, were categorized in slow, intermediate and fast volume progression. The 
annual growth rate in this study lay between of < 1.5% and > 6%. The established model predicts 
renal function based on annual percentage increase in kidney volume, calculated with an ellipsoid 
method. The rather new approach to quantify renal volume with the ellipsoid formula, using 
midslice tracing, is less time consuming compared with a stereological approach but probably 
less accurate.138,140 
 The annual average kidney growth is about 5.3% ± 4.0% and 5.36 ± 9.47%, assessed with 
MRI and stereological volume quantification.13,14 There is a strong correlation between left and 
right kidney volume increase and between cyst and total kidney volume.138 The increase in total 
kidney volume can be exclusively explained by cyst growth. Once total kidney volume reaches 
1,500 cm3, renal function decreases by about 5 ml eGFR per year.13 Chapman et al predicted 
progression to CKD stage 3 within 8 years with baseline htTKV of 600 cm3.137 Also kidney 
length seems to predict development to stage 3 CKD.139 Our results, described in section 2 
confirmed the negative correlation of eGFR with TKV and htTKV, as it has been shown in 
several studies.77,137,191 In fact, our statistical models seem to predict htTKV more precise than 
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eGFR, indicating htTKV being in general more accurate to predict diseases progression than 
eGFR does. A growing body of evidence shows that TKV is associated with ESRD prediction, 
hypertension, hematuria and proteinuria.139  
 
Are urinary markers qualifying as prognostic biomarker in ADPKD? 
 The identification of biomarkers predicting renal function and kidney volume is described 
in the results section. We investigated parameters originating from the glomerulus, proximal and 
distal tubules that may qualify as biomarkesr for prognosis prediction in early ADPKD. There is 
an unmet need to establish biomarkers to assess disease severity and predict prognosis. We 
focused on urine spot samples that are obtainable in a non-invasive way and are a standard 
procedure in most nephrological practices. The potential and promising urinary biomarkers 
osmolality, NGAL, Umod, KIM-1, CC16 and UACR were tested to predict eGFR and kidney 
volume. These biomarkers may reflect renal glomerular and tubular damages (figure 4). 
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Figure 4: Potential urinary biomarkers in ADPKD 
 
 The mechanisms by which markers occur in urine are impairment of the filtration barrier; 
substances that are in healthy kidneys held back by the filtration barrier are now passing. Tubular 
reabsorption may be diminished or tubular proteins may be upregulated by injury and cell 
damage, like KIM-1. Furthermore recruited inflammatory cells can release markers. The complex 
process of cystogenesis in ADPKD is characterized by increased tubular cell proliferation, fluid 
secretion into cysts, and abnormal cell polarity.192 Cysts develop from all parts of the nephron, 
and start to detach from the tubule by exceeding a diameter of 2 mm. Cysts ultimately leading to 
obstruction of tubules and urine flow through the compression of renal parenchyma. The damage 
leads to interstitial fibrosis and inflammation.156 
 In terms of biomarkers evaluation for ADPKD, we intended to combine several markers 
instead of using a single marker, assuming that modelling with more than one parameter will 
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allow more precise disease state and prognosis assessment. We investigated markers that are 
already well known to be abnormal in ADPKD, like urine osmolality and Albumin-Creatinine 
ratio with parameters that are so far un-investigated in ADPKD, like Umod and CC16. Urine 
osmolality in our study is, like shown by other investigators before, independently associated 
with kidney volume and kidney function.175 Among our investigated urinary biomarkers, KIM-1 
showed a strong correlation with TKV. NGAL has been extensively investigated as a biomarker, 
due to its rapid increase after kidney injury, in AKI, cardiac surgery and kidney 
transplantation.113,159-162 Urinary NGAL levels are increasing and even more pronounced in fast 
progressing ADPKD compared to healthy but the evidence is per se sparse.103 In our study 
NGAL was neither correlated with eGFR nor with TKV in univariante and multivariante 
regression analysis. The undetectable correlation may be caused by the properties of our cohort, 
composed of young patients with preserved renal function, as it was the case in the CRISP study. 
High levels of NGAL expression have been found in cystic epithelial cells in animal studies.177 
Decreasing levels of urinary Umod and positive correlation with renal function have been 
reported in various settings of CKD, like glomerulonephritis, diabetic nephropathy or 
tubulointerstitial nephropathy, potentially caused by loss of Umod secreting cells.115,118,119,163,164 
However, reporting Umod and CC16 levels in ADPKD for the first time, we are not able to detect 
associations with renal function or kidney volume.  
 In section three we investigated events of microhematuria in ADPKD in a longitudinal 
way. Microhematuria has been rarely investigated in ADPKD and requires time-consuming 
laboratory analyses to be detected compared with visible macrohematuria. Furthermore, 
micorhematuria can occur without patients notice. Episodes of gross hematuria before the age of 
30 are associated with worse renal outcome compared to subjects without gross hematuric 
events.9 The number of episodes and the age at which the first episode took place are predictors 
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for renal function decline.34 With our study, we extend the spare data available about 
microhematuria in ADPKD, especially in early disease state and young patients. Microhematuria 
is associated with different disease indices at baseline and also in a longitudinal fashion. Renal 
function, as eGFR, TKV as well as albumin-creatinine ratio are associated with microhematuria 
over disease course. Also flank pain and macrohemautria episodes are predictive for 
microhematuria. We clearly found differences in patients with microhematuria compared with 
patients without microhematuria at baseline. Patients positive for microhematuria may have a 
accelerated disease course in terms of eGFR, serum creatinine, 24-hour albuminuria and systolic 
blood pressure. Screening for microhematuria is not a clinical routine. Also the cut-off values for 
erythrocytes per high power field for microhematuria classification differ between laboratories. If 
microhematuria qualifies as biomarker for ADPKD and should be investigated on a regular basis, 
it needs to be clearly defined in further studies.  
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Outlook 
 Preclinical and clinical research gained immense knowledge about the pathogenesis of 
ADPKD. Still, despite the progress made there is no cure for ADPKD. In this thesis, I described 
the setup and implementation of an international cohort of ADPKD patients. This study will 
provide further insights into the disease course and morbidities and co-morbidities in ADPKD. It 
will facilitate new techniques and the establishment of guidelines for ADPKD treatment. The 
deeper insight into patient disease burden will support to reach these goals. The EuroCYST 
initiative with 1,100 patients in 10 countries in Europe is an unique approach and will close the 
gap of fragmented research emerging from small and local cohorts in Europe.  
 The availability of upcoming interventional treatment presupposes the selection of the 
right patients. Fast progressing young patients will probably benefit most of an intervention 
halting PKD progression and sustaining renal function or at least substantially delay progression 
to ESRD. Developed models of biomarker will support the selection. As shown in this thesis, 
several markers seem to qualify as biomarker in ADPKD. The approach of establishing models 
containing a series of marker will precise the assertions of disease state and progression. The 
model should be precise as possible but should also be practicable in clinical routine. Further 
investigation is necessary to finally draw conclusions which markers add valuable information in 
evaluating patients’ disease state and progression. 
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